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ABSTRACT
Severe Type 1 Diabetes Mellitus (T1DM) is known to have several negative effects on
skeletal muscle mass, a condition known as diabetic myopathy. One of these effects is the
atrophy of the glycolytic muscle fibers. However, the role of intensity of insulin treatment and
exercise modality in attenuating this loss in fiber cross-sectional area (CSA) has yet to be
determined. The purpose of this investigation was to examine the effects of 12 weeks of differing
intensity of insulin therapy and exercise modality on the CSA of plantaris muscle fibers of STZinduced T1DM rats. Fibers were identified by myosin heavy chain (MHC) composition. Rats
were divided into control sedentary (CS), T1DM-sedentary (DCT - conventional versus DITintensive insulin therapy, blood glucose 9-15mmol/l and 7-9mmol/l, respectively) and T1DMexercised (DRE- resistance, DHE-endurance, DCE-combined training, blood glucose 915mmol/l) groups. Exercises consisted of repeated weighted ladder climbs (50%, 75%, 90%, and
100% pre-determined max. carrying capacity, 1.1 m, 80°) or treadmill running (27 m/min, 6%
grade, 1hr) 5 days/week for 12 weeks. DCE animals performed resistance and endurance
exercise on alternating days. Following 12 weeks, diabetic sedentary (DCT, DIT) and diabetic
exercised (DRE, DHE, DCE) groups did not differ in body weight (BW) or plantaris wholemuscle weight, except where DIT BW was significantly greater than DRE (P<0.05). The
moderate hyperglycemia in DCT did not adversely affect muscle fiber CSA suggesting insulin
supplementation can protect against muscle fiber atrophy. In fact, intensive supplementation
(DIT) resulted in larger fast twitch MHC’s than either the control (CS) or conventional diabetic
(DCT) conditions (P>0.05) or aerobic exercise (DHE) in some instances (all fibers expressing
fast MHC’s except MHCIIx/IIb and MHCIIb – P>0.05). Surprisingly, DIT exhibited
ii

significantly larger MHCIIa and fewer hybrid fibers than any other group. MHCI fibers were
unaffected by either diabetes or exercise, however, exercised animals displayed changes in
percent fiber composition, including a significant proportion of hybrid fibers. These changes
suggested a shift in fiber type particularly from MHCIIx to MHCIIa. Resistance exercise,
whether alone (DRE) or in conjunction with aerobic training (DCE) resulted in significantly
larger MHCIIx and MHCIIb than CS. Treadmill running (DHE) resulted in less hypertrophy of
fibers expressing fast MHC than the other exercised groups. These findings indicate that
conventional insulin therapy is sufficient to maintain muscle mass and fiber CSA, while
intensive insulin therapy and exercise with conventional insulin therapy induce differential
changes in fiber percent composition and fiber CSA increases.

Keywords: type 1 diabetes mellitus, diabetic myopathy, skeletal muscle, myosin heavy chain
insulin, exercise, resistance training, endurance training, muscle fiber cross-sectional area,
muscle mass
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CHAPTER 1

1.1 Introduction: Diabetes Mellitus Overview

Diabetes mellitus is a term used to typically describe two distinct pathophysiological
states, which although differing in the underlying physiological basis of their dysfunction, have
in common a condition in which blood glucose levels are elevated (hyperglycemia) due to
impaired insulin response, which ultimately leads to microvascular, neurological and
macrovascular complications 1,2 . Over time, these complications often manifest themselves in
the form of retinopathy, nephropathy, peripheral and autonomic neuropathy, atherosclerotic
cardiovascular and cerebrovascular disease, and skeletal muscle myopathy 2–4. In fact, in the
United States diabetes mellitus is the leading cause of blindness, end stage renal failure, and nontraumatic limb amputation, and is also associated with a two-to-seven-fold increase in risk of
developing cardiovascular and cerebrovascular disease 5. Indeed, T1DM is a disease that not
only carries dire health consequences if proper management measures are neglected, but also
impacts a vast breadth of individuals globally.
Of the complications commonly associated with the disease, diabetic skeletal muscle
myopathy has historically received less research attention comparatively. However, the role of
maintaining a healthy skeletal muscle mass across the lifespan, in both healthy and diabetic
populations, has more recently become an area of intensive investigative efforts 6–9. In the
context of diabetic myopathy, the importance of maintaining healthy skeletal muscle mass and
function begins in adolescence and is vital in improving overall metabolic control, and
consequently reducing the progression rate of other complications. The role of exercise and
physical activity in not only the prevention of chronic disease, but in improving health and the

2

amelioration of various complications associated with diabetes mellitus has been identified as an
important therapeutic strategy in the management of the disease

8,10–12

. As skeletal muscle

exhibits a truly remarkable capacity to adapt to the various stressors exerted on it by exercise,
identifying the specific effects of differing modalities of exercise (i.e. aerobic, resistance,
combined) on skeletal muscle in individuals with diabetes provides a unique opportunity to
examine the effectiveness of exercise in the prevention and treatment of myopathy. The aim of
this chapter is to provide an overview on type 1 diabetes mellitus specifically, describe the
heterogeneity and plasticity of skeletal muscle fibers, and the pathology and mechanisms
underlying diabetic myopathy.
1.2 Classification and Diagnosis Criteria

Diabetes mellitus diagnoses generally fall into two etiopathogenetic categories: Type 2
diabetes mellitus (T2DM) in which elevated fasting blood glucose develops as the result of
resistance to insulin action, and Type 1 diabetes mellitus (T1DM) in which an autoimmune
mediated destruction of the pancreatic beta-cells in the Islets of Langerhans results in an absence
of insulin secretion, and in-turn elevated blood glucose 13. Symptoms that commence prior to a
diagnosis of Type 1 diabetes often include polydipsia, polyuria, weight loss and excessive
hunger, and are believed to be the result of the insulin secretion deficiency induced
hyperglycemia 13,14. The diagnosis of T1DM generally involves two measurements of a fasting
blood glucose level of 7 mmol/L or higher or any blood glucose level over 11 mmol/L, and has
been expanded to include glycated haemoglobin (HbA1C; a measure of glycemic levels over 3
months) of 6.5% or greater 15,16. One of the primary distinguishing features between T1DM and
T2DM that has garnered predictive diagnostic consideration in the clinical setting is the presence
of serological auto-antibodies specific to beta-cell auto-antigens. Over 90% of individuals with
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T1DM express one or more of the following auto-antibodies in the months or years prior to
onset: insulin reactive (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated autoantigen 2 (IA2A) and zinc transporter 8 (ZnT8A)17–19. Of particular concern is the increasing
number of individuals with T1DM who have developed insulin resistance, the primary pathology
underlying T2DM 20. It has been hypothesized that this may be a result of the intensive insulin
therapy program (that most individuals with T1DM partake in) driving the increase in average
body weight of T1DM patients that has been observed in recent decades 21,22.
1.3 Epidemiology

T1DM represents 5-15% of all diabetes mellitus cases, and it is estimated that there are
over 33 million individuals with T1DM worldwide, and although uncommon, as noted above,
individuals can be diagnosed with T1DM and T2DM simultaneously 14,23. It has also been
proposed that 5-15% of adults diagnosed with T2DM may actually have T1DM, due to
difficulties in discerning between T2DM and T1DM diagnoses, and thus the actual number of
T1DM cases may be underestimated 24. T1DM has also been referred to as juvenile-onset
diabetes as it commonly develops during adolescence in genetically susceptible individuals as
the consequence of an environmental trigger 14,25,26. However, it should be noted that although
the age-specific incidence rate rises in the years between infancy and puberty and then tends to
decline, nearly 30% of T1DM patients are diagnosed after age 20 5.
Alarmingly, T1DM incidence rates have been steadily increasing annually on a global
scale, reported to be as high as by 5.3% , 3.3%, 2.6% and 2.4% in the United States, Norway,
Germany and Finland, respectively 5,14,27–29 It is also of note to consider that the most substantial
increases in incidence seem to have been amongst children; in Europe, for example, children
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under 5 years have experienced the greatest increment 30. Based on the current trajectory for
T1DM incidence trends, the number of children under 5 years of age in Europe is expected to
double between 2005 and 2020 27. Considering the fact that the majority of individuals that are
diagnosed during childhood will likely face a life-time of erratic fluctuations in glycemic levels
and in turn an increased risk of developing future complications, the importance of early and
effective management is critical

31

.

1.4 Complications:

Type 1 diabetes has long been associated with a greater risk of mortality due to
complications, with estimates ranging from 5 – 10 times greater risk compared to individuals
without the disease 23. The majority of the complications associated with T1DM are classified as
either microvascular or macrovascular in etiology. Since the introduction of insulin therapy in
the management of T1DM, long-term complications such as retinopathy, neuropathy,
nephropathy and cardiovascular disease have represented the greatest contributors to morbidity
and mortality 1. The systemic nature of the metabolic dysregulation associated with T1DM and
thus chronic hyperglycemia results in pathological complications that are extensive in range. As
such, additional debilitating complications that arise as a consequence of T1DM include
blindness, end stage renal failure and non-traumatic limb amputation, all of which can contribute
to a chain of circumstances which accelerate the deterioration of health 5. In 1993, the Diabetes
Control and Complications Trial provided critical evidence for the role of intensive insulin
therapy (and thus strict glycemic control) in reducing the progression of these complications, and
identification of the underlying mechanism of hyperglycemia-induced damage has provided
insight into the underlying pathogenesis of macrovascular disease, establishing a basis for the
goals of T1DM management 2. Despite the benefits of intensive insulin therapy in attenuating
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the progression of the aforementioned complications, one of the drawbacks of maintaining rigid
glycemic control is the potential development of insulin resistance, which has been observed in
T1DM populations 32.
Of the many organs detrimentally affected by T1DM, skeletal muscle has received less
research attention. Skeletal muscle is the largest metabolically active organ by weight, the body’s
primary glucose sink, and central to insulin sensitivity and basal metabolic rate and experiences a
myriad of dysfunctions in response to T1DM collectively known as myopathy 33,34. Diabetic
myopathy is often clinically defined by lower muscle mass, weakness, a reduced physical and
regenerative capacity, as well as several other histopathological, hormonal, and metabolic
abnormalities 4,33–39. Interestingly, pathological alterations such as muscle fiber atrophy and
mitochondrial morphological abnormalities can occur in recently diagnosed T1DM patients (1 –
28 weeks duration) prior to the manifestation of diabetic neuropathy, indicating that skeletal
muscle is acutely sensitive to the T1DM milieu 34,40. When the array of physical and functional
consequences associated with diabetic myopathy are considered in conjunction with the
predominance of T1DM manifestation in adolescence, a significant period of muscle growth
and development, the importance of addressing diabetic myopathy is quite clear. A more detailed
discussion of the pathology and potential underlying mechanisms exacerbating diabetic
myopathy will be presented later in this chapter, after sufficient elucidation of skeletal muscle
physiology and muscle fiber heterogeneity is provided.

1.5 Skeletal Muscle Overview:

6

Skeletal muscle is a truly remarkable tissue, having occupied a fundamental role in
human evolution and survival, and continuing to act as a critical determinant of health and
disease. In humans it represents 40% of total body weight, 50-75% of all body proteins, and 3050% of all protein turnover 41,42. Skeletal muscle is essential to locomotion, stability/postural
maintenance, thermogenesis and whole-body metabolism; the heterogeneous nature of the
individual muscle cells/fibers also permits muscles to perform a wide variety of tasks spanning
the spectrum of motor control demands 33,43,44. The impressive variation in muscle fiber
structural and functional properties is mediated by different amounts and specific kinds of
proteins (of which there are a multitude of isoforms) which function together to define fiber
phenotype, and as such enable an exquisite adaptability to physical demands 42,44 . In
Hochachka’s “Muscles as Molecular and Metabolic Machines” the author provides an extensive
list of specific proteins (albeit only including the minimal requirements), which outline the
functional and structural muscle fiber components that describe a typical fast glycolytic fiber
phenotype. As such, the author fixates on the fact that this brief list of components alone would
require the regulated expression of over 100 genes, and thus the adaptive plasticity exhibited by
muscle fibers is theoretically only limited by the number of ways in which the contributing
isoforms are assembled 42.
Human skeletal muscle displays a remarkable capacity to adapt to the physiological
stresses imposed on it by physical activity and exercise demands. For example, an examination
of the vastus lateralis skeletal muscle properties of a world-champion sprint runner revealed a
high abundance of pure MHC IIX fibers (24%) that were highly transcriptionally responsive to
high intensity exercise, and a total glycolytic fiber population of 71% ; the power output of
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which were higher than any reported human values to date 45. Conversely, as East African black
athletes have long been regarded as dominant in endurance athletic events, investigation of
vastus lateralis muscle biopsies of Xhosa compared to Caucasian endurance athletes (matched
for training and racing distances) revealed that Xhosa runners exhibited lower plasma lactate
concentrations at 80% Peak Treadmill Speed (PTS) and significantly higher percentage
composition MHC IIa and lower MHC I compared to Caucasian runners, although oxidative
enzyme activities did not differ 46. The skeletal muscle phenotypic adaptations found in humans
occur along a broad spectrum and are implicated in not only athletic performance, but play a
significant role in the maintenance of health across the life span.
1.6 Fiber Type Nomenclature and Classification:

The process in which the heterogeneous properties of skeletal muscle fibers have been
elucidated and classified has been gradual, mirroring advancements in available scientific
techniques capable of investigating the differing functional, metabolic, and structural properties.
As such, the nomenclature has evolved accordingly, in order to appropriately catalogue these
findings and incorporating more information in each definition. Spangenburg and Booth provide
a description of this process, beginning as early as 1873 when Ranvier distinguished “red”
muscles that contracted slowly from “white” muscle that contracted fast 47. In the 1960’s these
muscles/fibers (type I and II) were further classified by their contractile properties as well as
their oxidative capacity, introducing a new sub-classification of type IIA and type IIB 48,49. The
refinement of analyses of metabolic properties of muscle fibers through microdissection of single
fibers also allowed the identification of widely varied enzyme activities between fiber types 50–52.
In the 1980’s, the use of electrophoretic separation techniques allowed correlation between MHC
composition, contraction speed and myosin ATPase to be identified 53,54. The MHC composition
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based classification of muscle fibers was furthered expanded with the identification of a third
unique MHC, MHC IIx/d 55–57. The subsequent improvements in immunohistochemical
techniques and comparison with histochemical myosin ATPase fiber typing permitted the
observation of human fibers histochemically staining positive for type IIB myosin ATPase to
actually expressing MHC IIx/d, and as such delineating a complete lack of MHC IIb in human
muscle 58. One of the more recent observations of importance to the MHC centered approach to
fiber phenotype nomenclature was the identification of fibers displaying heterogeneous MHC
composition; hybrid muscle fibers 59,60. Although not all muscle proteins associated with
specific MHCs are necessarily expressed in parallel, the central role of myosin as the molecular
motor and the differing MHC composition across fiber types suggest MHC expression as the
best available marker for fiber typing and communication purposes 44,47. Thus, according to the
MHC based classification and nomenclature of fiber types, fiber phenotype appears to occur
along a spectrum that could be described as MHC I MHC IIa  MHC IIx/d  MHC
IIb with hybrid MHC co-expression occurring “between” pure MHC fibers. This MHC
expression sequence is not requisite however; fibers co-expressing MHC I and IIx while lacking
MHC IIa have been identified 44,61.
1.7 Skeletal Muscle Fiber Diversity:

The diverse nature of the functional, structural, metabolic, and adaptive properties of
muscles fibers is essential to the ability of skeletal muscles to perform tasks of varying physical
demands. Phenotypic changes in response to neural and hormonal influences involve a myriad of
different molecular mechanisms responsible for mediating the activation of specific gene
programs, and in turn, specific isoform expression 44,47,62. The significant role of muscle activity
in the prevention and amelioration of chronic disease and complications suggests the importance
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of further investigation in elucidating activity (and inactivity) dependent signaling pathways in
order to identify potential therapeutic targets 44. As mentioned previously, MHC IIb is only
expressed in some mammals (i.e. mice, rats etc.). The complete absence of MHC IIb fibers in
human skeletal muscle is likely the consequence of body size’s role in functional demands,
where the energy metabolism for unit body mass is inversely related to body size (Kleiber’s law)
and basal metabolic rate (BMR) per unit mass varying with three-fourth power of body mass
44,63

. The thickness (diameter) of individual muscle fibers also appears to scale allometrically;

although surprisingly human cyclists have been shown to possess significantly larger vastus
lateralis fibers than those obtained from a single lion (Panthera leo) specimen, indicating
exceptions to this observation exist 64. Additionally, the maximum shortening velocity of each
fiber type appears inversely allometrically scaled, although this relationship is not fixed as horse
type I and IIa fibers maintain greater shortening velocities than humans despite significant body
mass disparity 44,65,66.
1.8 Effective Motor Neuron – Muscle Fiber Coupling… the Motor Unit:

As the primary function of fiber heterogeneity can be simplified to a necessity of
coupling specific isoforms in such a way that the physical requirements stipulated of a muscle
can be achieved efficiently, one of the most basic pairings is that of a motor neuron with
appropriate fiber constituents. Efficiently matching fiber phenotypes with specific neural activity
patterns is an essential aspect of utilizing the distinct properties of different fiber types and plays
a primary role in fiber remodeling in adult skeletal muscle 44. As such, the neuromuscular
system is organized into discrete units (motor units) consisting of a motor neuron and the
homogeneous muscle fiber population it innervates 67. In 1985 Henneman proposed the “size
principle” which theorized the orderly recruitment of motor units based on nerve cell size, where
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slow twitch motor units are recruited before larger fast twitch units 68. The activation of motor
units of increasing size is critical to the performance of fine motor skills, and therefore muscles
in the human hand /forearm tend (abductor pollicis longus) to contain a high number of motor
units despite a smaller absolute size comparatively, as determined by motor unit number
estimation (MUNE). As one of the health consequences of T1DM is neuropathy, MUNE has
been recommended as a measure to predict motor unit dysfunction in animals, and MUNE has
even been found to be lower in children with T1DM 69,70.
1.9 Myosin Isoform Contractile Properties:

The myosin isoforms present in skeletal muscle are the primary determinants of fiber
contractile properties, ATP consumption, and the fiber’s ability to respond to the neural demands
imposed on it. In accordance with the diversity of motor unit activity patterns, the contractile
performance and ATP consumption requirements of the different myosin isoforms occur across a
spectrum. The mechanical power generated by muscle fibers defined in terms of power is
characterized by the mechanical energy generated per unit of time, and as such is directly related
to the chemical energy released by ATP hydrolysis via myosin ATPase 44. Peak power output
values increase from slow MHC type I fibers to IIb fibers, which possess the highest peak power
values of all mammalian species; indeed, this range across fibers can be as high as 10 fold when
measured in vitro at low temperatures 44,71.
Mechanical power generation is determined by the interaction of the maximum isometric
force (Po) and the maximum unloaded velocity (Vmax), and the curvature describing this
relationship (a/Po) essentially describes the force sustained at a particular velocity 44. As such,
these parameters determining power output display differences between fiber phenotypes. The
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Vmax of muscle fibers are determined exclusively by myosin isoform, and show a pattern of
increasing velocity from slow fibers to fast fibers, with IIb fibers exhibiting the highest
maximum velocity 64,72,73. In fact, the higher overall proportion of pure MHC IIx fibers that have
been observed in world champion human sprinters and the fastest terrestrial species on earth, the
cheetah (Acinonyx jubatus), provide excellent examples for the superior speed of contraction
parameters bestowed by these fiber phenotypes 45,74,75. Maximum isometric force and specific
force is also higher in fast compared to slow fibers and this disparity has been suggested to be the
result of a greater number of strongly bound myosin heads compounded by greater force
production per head, comparatively 64,76–78. Thus appropriately, studies examining MHC isoform
content in the vastus lateralis muscle homogenates of body builders have reported higher
proportion (~15%) of IIx isoform compared to active young men (~5%) 79. However, it should be
noted that inferences made from muscle homogenates with the regular occurrence of hybrid
fibers co-expressing MHC isoforms, an assumption of a greater number of pure IIx fibers is
inappropriate unless detected at the single fiber level 75.
The myosin-ATPase activity levels of the different MHC isoforms also show marked
variation in rate of energy release and consumption, and thus contribute to the contractile
properties of muscle fibers. During isometric contraction in vitro, steady-state ATPase activity
has revealed that ATP hydrolysis rate also increases across the spectrum of fiber types, with IIb
fibers possessing the highest rate

80–82

. However, the amount of ATP consumed per unit time

per unit tension (tension cost) is lower in slow fibers, thus contributing to their role in
maintaining repetitive contractions and posture 80. Taken together, these functional parameters
support the role of different MHC fiber types being expressed in response to specific neural
activity patterns while permitting a wide range of dynamic movements.
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1.10 Metabolic Control:

The supply and regeneration of ATP during muscle activity is achieved through complex
metabolic regulation involving the integration of several different biochemical pathways. Indeed,
ATP hydrolysis provides the basis of all cellular energy supply, with 1 mol of ATP providing
~50-60 kJ energy, and during muscle contraction over 70% of ATP consumption is related to
myosin ATPase activity and the remaining 30% ionic transport 83,84. These pathways involve
different metabolic substrates and are most simply differentiated as anaerobic (O2-independent)
or aerobic (O2-dependent), and their relative utilization and efficiency of energy production
shows marked variation between fiber types in response to their respective contractile and
functional properties. ATP is generated anaerobically primarily through the phosphagen system
substrate creatine phosphate (PCr) and through anaerobic glycolysis/glycogenolysis, which
partially catabolizes glucose to rapidly supply energy while transitioning from rest and in the
early stages of physical activity. Conversely, aerobic generation of ATP is maintained by aerobic
glycolysis and mitochondrial oxidation of both glucose and free fatty acids, the complete
catabolism of which enables huge increases in yield of ATP/mol of substrate and a greater
capacity for sustained energy production 42. The delay in activation of aerobic metabolic systems
compared to the immediate reliance of anaerobic PCr and subsequently anaerobic glycolysis is
termed “metabolic inertia”, and this appears to be a pattern in which a decline in anaerobic ATP
production/capacity is matched with an inversely parallel increase in oxidative mitochondrial
ATP generation 85. It has been suggested that in exercise conditions in vivo in humans, the
limitations of the “cardiac pump” and thus O2 delivery to muscle mitochondria is a major
determinant of the activation of aerobic metabolic control 42,86. In accordance with the
impressive heterogeneity displayed in the mechanisms underlying neural activity patterns,
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sarcolemmal excitability, EC coupling and myosin contractile properties, fiber types display
pronounced differences across a continuous metabolic spectrum.
The different MHC fiber types exhibit considerable variation in fiber size and thickness,
generally following a trend of increasing cross-sectional area from type I fibers being the
smallest to the robust IIx and IIb fibers. This increase in fiber size is inversely related to the
expression of the oxidative enzyme succinate dehydrogenase (SDH) and positively correlated
with the glycolytic enzyme α-glycerophosphate dehydrogenase (GPD) 87. The reliance of smaller
fibers on primarily oxidative means of ATP generation is further supported by the presence of an
increased absolute number and ratio of capillaries to fibers, as well as an increased relative
proportion of mitochondrial volume (6%, 4.5% and 2.3% in MHC I, IIa, IIx respectively) 88,89.
Additionally, the mitochondria of slow oxidative fibers also exhibit morphological differences in
the form of densely packed cristae 90. From an enzymatic perspective, citric acid cycle (TCA)
enzyme activities (essential to aerobic metabolism) are over twice as high in slow fibers
compared to fast fibers in rabbit muscle 91. The fundamental involvement of aerobic metabolism
in sustaining muscle activity during repetitive contractions is further complemented by increased
glucose uptake capacity, GLUT4 (glucose transporter) protein expression, and myoglobin
content in slow compared to fast fibers 92–94. Interestingly, myoglobin is nearly absent in IIb
fibers, and in humans oxidative fibers exhibit ~50% higher content than fast glycolytic fibers
94,95

. In terms of mitochondrial oxidation, FFA’s contribution to TCA is also higher in slow

fibers compared to fast fibers, and slow fibers have also shown greater O2 consumption when
maximally stimulated (0.048 mM/s and 0.022mM/s in soleus and gastrocnemius, respectively) 96.
The larger, glycolytic fibers exhibit enzymatic and metabolic properties that contrast
those of the smaller, oxidative fibers. The function of anaerobic metabolism in rapidly producing
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energy is apparent when comparing the glycolytic power output ; during short duration, intense
activity in vivo in humans fast fibers consume 2.5 mM/s of ATP compared to 1.2 mM/s in slow
fibers 97. This rapid anaerobic glycolytic production of energy is aided by the fact that at rest, fast
fibers display slightly higher PCr content as well as much higher glycogen content 42,97,98.
Interestingly, the amount of PCr available for use as metabolic substrate appears to be more
dependent on fiber hypertrophy and not adjustments in concentration; this finding corresponds
with the greater potential for hypertrophy of MHC type II glycolytic fibers 99. In terms of
activation time-course, Bangsbo et al. demonstrated the initial reliance on PCr metabolism
followed by gradual increases in anaerobic and finally aerobic glycolytic and mitochondrial
metabolism in healthy human subjects, with PCr supplying 80% of power output for initial 30s,
45% for 60-90s, and ~30% at 120s onwards 85. Similar to PCr metabolism, anaerobic glycolysis
is capable of producing high rates of power output and heavily relied upon by fast fibers 97.
Indeed, all of the enzymes involved in glycolytic metabolism, including the rate-limiting
phosphofructokinase (PFK) show much higher activity levels in fast compared to slow fibers
51,52

. The sympathetic nervous system stimulated hormonal release of epinephrine also displays a

greater effect on glycogen breakdown in fast fibers, likely indicative of epinephrine’s role in the
“fight-or-flight” response necessitating rapidly available energy 100. As would be expected, the
varied metabolic properties of specific fiber types results in a range of energy consumption
demands during maximal isometric contraction in humans 101. As such, MHC type I fibers have
been found to consume 6.5 mmol/kg/s, while IIa and IIx fibers have been measured consuming
17.6 mmol/kg/s and 26.6 mmol/kg/s, respectively 44,102.

15

1.11 Satellite Cells, Growth, Regeneration and Fiber Type:

A unique feature of skeletal muscle is the post-mitotic, multi-nucleated nature of
individual muscle fibers. As a result of this terminal differentiation state, the capacity for growth
(hypertrophy) and regeneration exhibited by muscle fibers is largely due to the presence of a
small population of progenitor cells found between the basal lamina and sarcolemma, known as
satellite cells 103–108. First identified in 1961, satellite cells (SC) normally exist in a quiescent
state, but in response to a number of different stimuli these cells become activated, proliferate,
and fuse to existing fibers becoming new myonuclei 106. A number of molecular markers
differentially expressed by SC’s have been identified, and include but are not limited to: Pax 7,
Pax 3, MyoD, Myf5, NCAM/CD-56; however, myogenic regulatory factors such as MyoD and
Myf5 are not expressed by quiescent SC 108,109. In terms of SC activation and signaling, a number
of contributing mechanisms have been proposed, all of which have been described as
contributing to the specific “niche” in which SC exist outside of the muscle fiber 108. Factors that
have been identified to contribute to the maintenance of this specific niche and SC activation
include the extracellular matrix (ECM), vascular and neural networks, myofiber secreted factors,
mechanical tension, Wnt and Notch signaling, and hormones such as IGF-1 108,110–123. Although
the exact mechanisms and interactions of these niche components is beyond the scope of this
review, the topic has been reviewed extensively elsewhere 106–108. In fiber hypertrophy, the
contribution of SC to the existing myonuclei pool is believed to be driven by increases in fiber
cytoplasm, as myonuclei are unable to divide, and the nuclei to cytoplasm ratio or “myonuclear
domain” appears to be constant in adult fibers. Furthermore, SC have been shown to play a
critical role in fiber regeneration in response to exercise and myotrauma, where ablation of
Pax7+ SC abolishes the regeneration capacity in adult muscle 124–126. Physical exercise such as
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resistance training has also been shown to be highly effective at increasing the density and
activation of satellite cells, as determined by immunohistochemistry and electron microscopy
109,127–130

.

SC content appears to vary based on muscle fiber type, with slow fibers generally
possessing a greater number of SC’s than fast fibers and potentially maintaining intrinsically
different properties based on fiber type of origin 109,131–133. For example, the percentage of
satellite cells in the soleus has been found to be two to four times higher than that of the EDL
and tibialis anterior (TA) muscles, composed predominately of slow and fast twitch fibers,
respectively. Interestingly, SC content in sedentary elderly compared to young individuals has
been shown to be reduced in fast fibers specifically, and comparatively elderly subjects tend to
experience reduced increases in SC density in response to resistance training 107,134–136. This
fiber-type specific SC dysfunction does not appear to be exclusive to aged individuals; satellite
cell abnormalities have also been observed in models of diabetes, in which fast fibers are the
most susceptible to diabetic myopathy 137. For example, in steptozotocin (STZ) rodent models of
T1DM, SC activation has been found to be greatly reduced, and overall regeneration capacity
attenuated following myotrauma, as well as SC exhibiting reduced MRF expression and
impaired differentiation 137–141. Although the combined effects of oxidative stress, a chronic
low-grade inflammatory profile, and impaired ECM remodeling as a result of the diabetic milieu
have been suggested to contribute to these dysfunctions, the T1DM specific expression of
plasminogen activator inhibitor-1 (PAI-1) and myostatin (MSTN) are particularly interesting 137.
MSTN is a known negative regulator of muscle mass and a strong repressor of satellite cell
activation which shows elevated protein and gene expression in T1DM

142–146

. PAI-1 is a

hormone involved in the regeneration process and ECM turnover rate, impedes fiber recovery

17

following injury, contributes to SC regulation and is found to be elevated in STZ diabetic rats
34,141,147–151

. Although both of these regulatory mechanisms contribute to diabetic SC dysfunction

independently, the positive correlation between glucocorticoid levels (which are elevated in
diabetic myopathy), PAI-1 expression and MSTN gene expression would seem to indicate an
inter-related SC dysfunction pathogenesis 34,147,148,152,153. Furthermore, the fast fiber specific
atrophy in both diabetic and aged populations with the presence of SC abnormalities could also
suggest some overlap in the pathogenesis of the two atrophic states, providing further impetus
for additional fiber specific myopathy and sarcopenia research investigation.
1.12 Diabetic Skeletal Muscle Myopathy Characterization:

As stated previously, diabetic myopathy is a condition typically characterized by reduced
muscle mass, muscular weakness, diminished physical work capacity and decreased maximal
force production 4,34,36,37,154. Furthermore, the reduced muscle mass and force production that
manifest in diabetic myopathy seem to be related to muscle fiber atrophy, with fast glycolytic
fibers (MHC IIx, IIb) appearing to be the most severely affected whereas slow fibers are
relatively unaffected

33,34,155–159

. Additionally, children with T1DM have also been found to have

reduced motor unit number estimates (MUNE) compared to non-diabetic children, indicating the
possible role of neuropathy in diabetic myopathy progression 70. However, recently diagnosed (1
to 28 weeks) T1DM patients have also been shown to exhibit fiber atrophy, Z-disk disruptions
and mitochondrial abnormalities prior to the onset of any neuropathy, indicating that skeletal
muscle is acutely and detrimentally sensitive to the diabetic milieu 34,40,160. In addition to these
complications, diabetic myopathy reduces the regenerative capacity of muscle fibers, with
elevated levels of MSTN and PAI-1 negatively impacting SC activation and recruitment 141,145.
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As such, it is quite apparent that diabetic myopathy embodies a myriad of dysfunctions that
collectively contribute to functional and physiological consequences.
Although diabetic myopathy has historically not received the same level of research
attention as other complications associated with T1DM, maintaining a healthy level and quality
of muscle mass is central to the maintenance of overall physical health. As skeletal muscle is
responsible for enabling locomotion, as well as serving as the primary glucose sink and
metabolic regulator, investigating the underlying pathological mechanisms and determining
intervention strategies such as specific exercise modalities is crucial to attenuating the
progression of complications related to diabetic myopathy 33,34. As T1DM is most often
diagnosed in children and adolescents, and skeletal muscle undergoes significant development
and growth during childhood and puberty, early intervention in preventing the onset of the
dysfunctions associated with diabetic myopathy is of critical importance 34. The findings of
several studies investigating the physical work capacity of adolescents and adults with T1DM are
somewhat challenging, as many studies have indeed shown reduced capacities compared to nondiabetic cohorts, while other studies have reported no apparent physical impairment in
performance 34,161–165 Additionally, some of the studies in which reduced submaximal and
maximal workload were observed found that the degree of capacity detriment corresponded
inversely to metabolic control (HbA1c), introducing question as to whether poor metabolic
control is the result or the cause of this reduced physical capacity 34,161,162. In fact and somewhat
surprisingly, some human T1DM studies have even reported an increase in the relative percent
composition of fast fibers, as well as an increase in glycolytic enzymes 34,38,39. It should be noted
that these findings could be the result of the individuals in these studies maintaining excellent
glycemic control and insulin therapy management 34. Further complicating this, the use of
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functional measures such as VO2 max and PWC170 (submaximal exercise) do not necessarily
indicate muscle and fiber specific dysfunctions, as such measures involve the interaction of both
the cardiovascular and skeletal muscle systems 34.
The use of animal models such as the alloxan, STZ or Ins2Akita+- diabetic mice and rats
have provided a wealth of information regarding the impact of diabetic myopathy on whole
skeletal muscle and individual fibers. For example, a study comparing the STZ and Ins2Akita+/diabetic mice models to control animals after 8 weeks of diabetes found significantly reduced
gastrocnemius-plantaris-soleus mass (control 0.16 +- 0.005g, Ins2Akita+/- 0.12 +- 0.003g, STZ
0.12 +- 0.01g) and IIB/D fiber size (control 2241 +- 144 µm2, Ins2Akita+/- 1294 +- 94 µm2, STZ
1768 +- 163 µm2) in the diabetic animals compared to controls 166. STZ rodents have also shown
muscle specific loss in force, where soleus or slow fibers show no loss in force and EDL or fast
fibers show impaired force production 155,156,167. Another study using a 90% partial
pancreatecomy rat model of diabetes found that after 8 weeks of diabetes both type I and II
fibers occupied ~25% and ~45% less area, respectively, as well as diabetic animals exhibiting
45% lower gastrocnemius-plantaris-soleus complex mass and significantly lower absolute force
production 168. Surprisingly, some studies have actually reported increases in relative force
production

34,169,170

. This finding may seem antithetical when compared to other studies, Krause

et al. have postulated that this finding may be caused by altered Ca2+ transients in the fibers, as
STZ rats have been shown to exhibit hyperactive Ca2+ kinetics and SERCA activity 34,171
Although a number of other animal studies display findings similar to these, the differential
severity of atrophy and loss of force production could be a result of the duration of diabetes,
different experimental glycemic ranges due to the presence or absence of insulin, or even the
dosage of diabetes-inducing compounds like STZ administered. For example, the addition of
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various doses of STZ (0.25 – 3.0 mg/ml of a glucose-analogue used to induce pancreatic betacall destruction) to myoblasts in vitro was found to show that both chronic and acute exposure
resulted in reduced proliferative capacity in a dose- dependent manner, implicating STZ in fiber
dysfunction independent of systemic hyperglycemia 172. Furthermore, studies investigating the
effect of different dosages of STZ (60 mg/kg, 80 mg/kg, 100 mg/kg and 150 mg/kg) found
alterations in metabolic enzymes in higher dosage groups, and rats administered lower doses
responded better to insulin treatment 173. As such, some researchers have adopted lower
concentration, multi-dose STZ administration methods in an attempt to avoid complications
resulting from STZ independent of beta-cell destruction 174,175. Another issue amongst studies
using rodent models of diabetes is the fact in many cases the secretion or administration of
exogenous insulin is absent, and as a result these animals often have extremely high blood
glucose levels for extended periods of time, likely further exacerbating muscle myopathy and
making translation to human muscle difficult.
1.13 Pathological Contributors and Underlying Mechanisms:

Although the underlying mechanisms believed to primarily contribute to the atrophy and
reduced force production observed in cases of diabetic myopathy are hyperglycemia and an
abnormal protein synthesis-degradation balance, a number of additional pathological contributors
have also been identified

33,34

. For example, the metabolic hormones adiponectin and leptin may

not directly contribute to muscle fiber atrophy per se, but the metabolic effects of their abnormal
expression patterns in T1DM may contribute to diabetic myopathy. Adiponectin and leptin are
adipokine hormones that are known to increase insulin sensitivity and fat metabolism, and have
been found to be increasingly and decreasingly expressed, respectively, in individuals with
T1DM 33. Although leptin levels may be decreased in individuals with poorly controlled T1DM,
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insulin therapy has been shown to recover leptin expression in children and STZ rats 33,176,177.
Interestingly, the elevated expression of adiponectin found in individuals with T1DM appears to
arise independent of glycemic control, and has been shown to be positively correlated with
intramyocellular lipid (IMCL) accumulation in the skeletal muscle fibers of non-diabetic mice
20,33,178,179

. Higher levels of IMCL have also been observed in the skeletal muscle of humans

with T1DM and STZ rodents, and have been suggested as contributing to altered insulin
sensitivity 20,166,180. Coleman et al. have theorized that increased IMCL content associated with
elevated adiponectin expression in T1DM could be the result of a metabolic compensatory
mechanism in which lipids are removed from the circulation and stored within muscle fibers 33.
Similar to other T1DM complications such as vascular disease and neuropathy,
hyperglycemia resulting from a lack of pulsatile insulin release is considered a primary
pathological mechanism in diabetic myopathy. Hyperglycemia resulting from T1DM accelerates
the process of glycation, which occurs normally with aging, and results in the formation of crosslinkages between proteins known as advanced glycation end products (AGE) 181,182. AGE
accumulation in both serum and muscle has been established as contributing to diabetic
complications, and has even been associated with reducing motor function and grip strength in
non-diabetic elderly individuals 2,181,183–186. In T1DM muscle, AGE accumulation appears to
occur primarily in fast fibers, but increases in the AGE content of muscle fiber SERCA pumps
has also been reported 183,187,188. In essence, increased AGE content in myofibrillar protein
represents a post-translational modification in which myosin structure and function is negatively
affected; for example, glycation has been shown to reduce in vitro myosin motility and modify
molecules in the ECM 2,189.
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Hyperglycemia also promotes the activation of the polyol pathway, in which the enzyme
aldose reductase (AR) inadvertently depletes NADPH through the reduction of excess glucose to
sorbitol, and in turn reduces the regeneration capacity of the intracellular anti-oxidant glutathione
2

. As such, chronically elevated levels of reactive oxygen species (ROS) and oxidative stress

develops and is believed to contribute to the diabetic myopathic condition 34,190. Support for this
concept is provided by the findings that the use of aldose reductase inhibitors (ARI) have been
shown to ameliorate contractile function and muscle fiber area in STZ diabetic rats 34,191,192. In
terms of the preferential atrophy of fast fibers, fast fibers have been reported to exhibit a high
degree of mitochondrial free radical leak, and the reduction in anti-oxidant defense due to polyol
pathway activation could be considered to contribute to this atrophy 193. In fact, a study
investigating the fiber-specific responses to cachectic stimuli found that mice injected with
lipopolysaccharide endotoxin displayed muscle/fiber type specific responses; the fast vastus
lateralis muscle expressed significantly higher levels of ROS and E3 ubiquitin ligases atrogin-1
and muscle ring finger-1 (MuRF1) compared to the slow soleus muscle 194. Conversely, the slow
soleus muscle was found to express enhanced nitric oxide (NO), inducible NO synthase (iNOS)
and antioxidant genes in response to the oxidative stress “insult”, which the researchers
suggested could be a mechanism by which slow fibers display resistance to oxidative stress
induced atrophy 194. The E3 ubiquitin ligases atrogin-1 and MuRF1 have been identified as
playing an important role in skeletal muscle atrophy, and have been reported to be inactivated by
IGF-1, which happens to be reduced in adolescents and adults with T1DM 195–201. In addition to
increased atrogene expression, 21 days of STZ diabetes in rats has been reported to reduce
expression of MRF’s myogenin, MyoD and Jun D concomitantly with decreases in antioxidant
levels and synthesis of CK and myosin light and heavy chains 139. Indeed, the administration of
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the steroid hormone dehydroepiandrosterone (DHEA) and subsequent amelioration of MRF and
antioxidant expression, as well as protein synthesis, has been suggested by the authors to support
the atrophic role of oxidative stress in STZ diabetes 139.
The dynamic nature of muscle mass, undergoing frequent fluctuations of both protein
synthesis and degradation activity, suggests that an imbalance in protein anabolism and
catabolism likely contributes to the diabetic myopathy state. Indeed, the presence or absence of
insulin has a substantial effect on the balance between protein synthesis and proteolysis in T1DM
muscle 202–204. However, most evidence supports the notion of insulin playing a role in inhibiting
proteolysis instead of actually increasing protein synthesis in TIDM 34,205,206. This matter is
somewhat complicated by reports in which insulin has been shown to stimulate increased rate of
protein synthesis in STZ diabetic rats, but not in human adults and adolescents with T1DM 207–
209

. However, in cultured C2C12 myotubes, the addition of insulin and IGF-1 have been shown

to increase protein synthesis by 62% and 35%, respectively, although these results would seem to
indicate some inherent difference between insulin action in vivo versus in vitro models 210.
Accordingly, the aforementioned researchers indicated that insulin and IGF-1 both acted to
stimulate the phosphorylation/activation of the phosphatidylinositol-3 kinase (PI3K) – Akt –
mammalian target of rapamycin (mTOR) pathway, a signaling pathway strongly associated with
muscle growth and hypertrophy 195,210. The activation of the PI-3 K signaling pathway by insulin
acts to inhibit the ubiquitin-ligase atrogin-1, in turn negatively regulating the expression of
ubiquitin and thus the proteolytic ubiquitin-proteasome (Ub-P) pathway 206,211. Furthermore, the
fact that components of the Ub-P proteolytic pathway are often found to be upregulated in
T1DM corresponds with the atrophic condition commonly observed in diabetic myopathy
34,139,206,212,213

. Interestingly, Akt expression and activation in STZ rats has been found to be
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lower in fast muscles, but not in slow muscles compared to controls, and thus may indicate
another aspect of the fiber specific atrophy in diabetic myopathy 34,214. The infusion of human
recombinant IGF-1 in STZ rats has also been shown to partially restore growth rate in diabetic
growth-arrested rats, and further addition of insulin resulted in completely restored growth 34,215.
As IGF-1 and insulin are structural homologues which act through similar receptors, increasing
IGF-1 content local/autocrine to skeletal muscle through interventions such as resistance exercise
could provide promising results for diabetic myopathy216,217. In a model of diabetes in which rats
were partially pancreatectomized (~90%) and subjected to 8 weeks of progressive resistance
training, exercise was found to increase soleus and gastrocnemius-plantaris complex wet weight
compared to sedentary rats and partially restored IGF-1 concentration 204,218. Interestingly, the
same increases in IGF-1 concentration in the non-diabetic acutely exercised animals was not
observed, and the authors of these studies suggest that the increase in circulating IGF-1 in
diabetic rats may act in a compensatory manner 218.
1.14 Role of Exercise in T1DM Management:

Engaging in regular physical activity and exercise is an important component of the
health regimen in T1DM, and is associated with an increased life expectancy and reduced risk of
developing complications, and even an inversely proportional relationship to mortality risk 11,219–
222

. Some of the additional health benefits that exercise confers to individuals with T1DM

include (but are not limited to) improved cardiorespiratory and vascular health, decreased insulin
requirements, improved endothelial function and overall quality of life 220,223,224. Despite these
established benefits, it has been reported over 60% of adults with T1DM do not partake in the
recommended levels of physical activity, and due to a scarcity of specific research in the area,
the appropriate type, duration, frequency and intensity of physical activity necessary to induce
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glycemic improvements still remains somewhat unclear 219,220,225. A contributing factor to the
poor adherence to a therapeutic physical activity routine in individuals with T1DM is the fear of
post-exercise induced and late-onset (nocturnal) hypoglycemia 226,227. Interestingly, contrary to
the known risk of post-exercise hypoglycemia in moderate-intensity aerobic exercise, it has been
observed that anaerobic exercise (such as resistance training) can actually induce post-exercise
hyperglycemia, further highlighting the benefits of characterizing the divergent effects of
differing exercise modalities in T1DM 228. It follows that the focus of a large number of exercise
interventions in T1DM patients has typically been on improving glycemic control measuring
markers like glycated hemoglobin (HbA1c) or fructosamine in order to reduce the risk of
cardiovascular disease and related complications 219,228. Although these studies do not necessarily
examine the effects of exercise on skeletal muscle mass and fiber size specifically, improving
glycemic control through exercise and thus restoring euglycemia could confer improvements in
muscle mass in T1DM patients.
In terms of preventing diabetic myopathy, or maintaining/ improving muscle mass with
exercise in T1DM patients, research investigating the effects of different modes of exercise on
skeletal muscle/fiber size is somewhat sparse. The molecular and physiological effects of
progressive resistance training on skeletal muscle and the corresponding strength gains and
muscle hypertrophy that occurs in response has been studied extensively in healthy humans and
rodents, and has shown promise in attenuating the deleterious effects of diabetic myopathy 229–
231

. In one rodent study, partially pancreatomized (~90%) diabetic rats subjected to 8 weeks of

progressive overload resistance training were shown to exhibit significant soleus and
gastrocnemius-plantaris muscle hypertrophy despite diabetes resulting in lower muscle wet
weight compared to healthy animals 232. Another study using STZ-induced T1DM rats
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performing a 1 meter weighted-ladder climb progressive resistance training protocol for 5 weeks
(5 sets of 4 repetitions/climbs) resulted in significant hypertrophy of the flexor hallucis longus
(FHL) muscle as determined by increased FHL weight-to-body weight in trained versus
untrained animals 233 In a human study investigating progressive resistance training in Hispanic
older adults with T2DM, 16 weeks of resistance training (3 times per week, 3 sets of 8
repetitions) was found to significantly increase mean upper and lower body strength, whole-body
lean mass, muscle quality (strength per unit volume of muscle) and the CSA of type I and type II
muscle fibers (vastus lateralis) 234. It appears that despite the diabetic milieu’s propensity for
decreasing muscle mass, resistance training is still capable of eliciting skeletal muscle
hypertrophy; however, closer examination of the MHC fiber-specific responses to resistance
training in T1DM is still warranted in order to better characterize the differential responses of the
heterogeneous fiber population to resistance training in T1DM.
Similarly, although aerobic endurance training is typically associated with increasing
skeletal muscle mitochondrial content, oxidative enzymes, capillary density and overall oxidative
capacity, it has also been shown to play a role in muscle hypertrophy and muscle atrophy
prevention 229,230,235,236. Hence, aerobic endurance training may also be a candidate for the
prevention and treatment of diabetic myopathy in addition to its beneficial effects on insulin
sensitivity and glycemic control 237. Several studies on healthy humans have shown that 12
weeks of cycle ergometer endurance training (20-45 mins, 60-80% HRR, 3 sessions per week) is
capable of inducing both whole-muscle and fiber hypertrophy in young men and older men and
women 235,238,239. In STZ-induced T1DM rodents, 8 weeks of progressive treadmill training (5
days per week, 30 min – 1.5 hr per day) was found to significantly increase gastrocnemius whole
muscle weight and fiber size compared to sedentary diabetic animals, and this anti-atrophic
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effect of endurance exercise was shown to be at least partly due to the downregulation of MuRF1 mRNA in diabetic exercised animals 240. Further support for the notion of aerobic exercise
conferring protection from fiber atrophy in T1DM is provided by the finding that PGC-1α, the
master regulator of mitochondrial biogenesis significantly upregulated in response to endurance
exercise, appears to also inhibit skeletal muscle atrophy through inhibition of FOXO3which
activates atrogin-1 and MuRF-1 236,241. Indeed, the fact that glycolytic fibers contain lower levels
of PGC-1α than oxidative fibers has been proposed as one of the factors which contributes to
glycolytic fiber susceptibility to fasting and glucocorticoid induced atrophy 242,243.With these
skeletal muscle specific benefits of aerobic endurance training considered alongside the postexercise hyperglycemia inducing capacity of anaerobic resistance training, the concept of
combined exercise training to prevent diabetic myopathy is particularly intriguing. In healthy
adults, combining resistance and aerobic endurance training elicit improved muscle fiber CSA
hypertrophy after 5 weeks in the vastus lateralis compared to resistance training alone (17%
versus 9%) in young men, while other studies in older men have shown no difference in muscle
hypertrophy (11% ) between the two 244,245. Interestingly, 14 weeks of concurrent lower body
endurance and upper body resistance training in active elderly has been shown to induce similar
increases (38%) in satellite cell counts in muscle samples from both deltoid and vastus lateralis
muscle samples, primarily in type II muscle fibers 135. As such, investigating the potential
benefits of combining resistance training with aerobic endurance training in T1DM could
provide insight into whether these aforementioned training effects are preserved in the diabetic
milieu and could represent an ideal exercise training modality by reducing the risk of postexercise hypoglycemia and improving insulin sensitivity while increasing whole muscle and
fiber hypertrophy.
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1.15 Concluding Remarks:

Diabetic myopathy represents a complication associated with T1DM that warrants further
research for a number of reasons. The rate of T1DM incidence has been reported to be increasing
on a global scale, and the greatest increment increases have been observed in children under the
age of 5 years old 5,14,27–30. Since skeletal muscle undergoes significant growth and development
during childhood and adolescence, the increase in children affected by T1DM at a young age has
potential to increase the severity of the negative effects of diabetic myopathy, manifesting in
serious health and functional consequences. Furthermore, in an increasingly aging society,
sarcopenia or the muscle loss (predominately in glycolytic fibers) associated with old age has
been shown to be more prevalent in older adults with latent autoimmune diabetes and T2DM
compared to non-diabetics 246–249. Improving our current understanding of how to prevent the
development or attenuate the progression of diabetic myopathy may prove to be critical in
maintaining skeletal muscle health across the lifespan of patients with T1DM.
Independent of the epidemiological relevance of researching diabetic myopathy, the
current body of literature is subject to some criticism in terms of translational ability to humans
with T1DM. The STZ-induced T1DM rodent model that has been used for the majority of
diabetic myopathy studies to date presents a few challenges in terms of experimental design that
make it difficult to compare to humans with T1DM. Firstly, the majority of STZ T1DM rodent
studies have utilized single high-dose injections of STZ in order to induce diabetes, usually
between 60-70 mg/kg in rats and 120-250 mg/kg in mice 157,166,169,180,250–258. As high doses of
STZ (100 mg/kg – 150 mg/kg) injected in rats has been found to result in premature death, and
STZ both in vivo and in vitro has been shown to have deleterious effects on skeletal muscle
independent of hypoinsulinemia-hyperglycemia in a dose dependent manner, attempts to reduce
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the myotoxic role of STZ per se on skeletal muscle should be a priority in STZ T1DM models
investigating diabetic myopathy 172,173. A second issue with STZ T1DM models of diabetic
myopathy is that the majority of these aforementioned studies do not include insulin therapy in
their experimental design, general resulting in a severe diabetic state. Insulin therapy is
foundational to the management of T1DM in humans, and a near absence of circulating insulin in
rodent models of diabetic myopathy limits the degree to which results can be extrapolated to
humans with T1DM. Moreover, insulin is known to contribute to the maintenance of muscle
mass primarily through the inhibition of skeletal muscle proteolysis, and even small amounts of
circulating insulin can significantly inhibit protein breakdown; extreme hypoinsulinemia likely
exacerbates the diabetic myopathic condition in STZ T1DM models 259,260. A consequence of the
chronic hypoinsulinemia exhibited by STZ T1DM rodents is of course, hyperglycemia, which in
many rodent models has been reported to be between 20 and 38.8 mmol/l, with some studies
reporting blood glucose concentrations as high as 44.4 and 56.5 mmol/l 157,166,168,180,250,252,253,255–
257

. Once again, these extremes in resting blood glucose concentration are unrepresentative of the

general T1DM population (aside from during the weeks-months prior to diagnosis/insulin
therapy), and thus detract from the translational capacity of these models. With these limitations
in mind, one of the aims of the present study was to investigate the role of conventional (blood
glucose 9-15 mmol/l) compared to intensive (7 – 9 mmol/l) insulin therapy on skeletal muscle in
multiple low-dose STZ (20 mg/kg) injected T1DM rodents through the use of subcutaneously
implanted insulin pellets. The blood glucose range for conventional insulin therapy was selected
in order to provide a comparable level of glycemic control to the general T1DM population,
whereas intensive insulin therapy represents T1DM patients with tightly controlled blood
glucose levels 174,261.

30

As exercise is known to produce significant adaptations in skeletal muscle with adaptive
responses varying in response to specific exercise modality and muscle fiber type, the role of
exercise training on the skeletal muscle in T1DM specifically also warrants further research
attention. As previously discussed, resistance, aerobic endurance and combined exercise training
are particularly interesting potential therapeutic avenues in treating and preventing the
development of diabetic myopathy, largely due to their beneficial muscle-specific effects.
However, the majority of studies on exercise training in T1DM have focused primarily on
improving indices glycemic control rather than examining the effects of exercise modality on
skeletal muscle and specific muscle fiber populations 219,223,228,237,262. Moreover, the few exercise
training studies that have examined muscle hypertrophy in response to training have either
utilized extreme experimental conditions such as synergistic ablation to induce chronic overload,
or have neglected to incorporate insulin therapy and representative blood glucose ranges,
limiting their translational capacity to humans 232,253,263. With consideration of the myriad of
adaptive responses of skeletal muscle to exercise modality, comparing the effects of different
exercise modalities within the same model of T1DM could provide insight into how specific
skeletal muscle fibers adapt despite T1DM. Furthermore, characterizing these differential
adaptations in T1DM in response to specific exercise modalities could also allow for the
determination of exercise training protocols designed to optimize the maintenance of skeletal
muscle mass while conferring improved glycemic control. Hence, the other primary aim of the
present study was to examine the effects of resistance, aerobic endurance and combined exercise
training on MHC muscle fibers in a multiple low-dose STZ (20 mg/kg) rodent model of T1DM
receiving conventional insulin therapy (blood glucose 9-15 mmol/l). The conventional blood
glucose range in exercise trained animals, in addition to better representing the general T1DM
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population, was selected in order to also permit comparison of exercised animals with intensively
treated sedentary animals to identify whether exercise in moderately hyperglycemic conditions is
comparable or superior to intensive insulin therapy in maintaining/increasing skeletal muscle
mass. This model of T1DM in which experimental conditions may allow improved translation of
results to humans in conjunction with submitting animals within the same model of T1DM to a
range of exercise modalities should produce novel insights into the diabetic myopathy and its
treatment.

32

1.16 References:

1.

The Diabetes Control and Complications Trial Research Group. The effect of intensive
treatment of diabetes on the development and progression of long-term complications in
insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).

2.

Brownlee, M. The pathobiology of diabetic complications. Diabetes 54, 1615 (2005).

3.

ADA. Diabetes Mellitus and Other Categories of Description of Diabetes. World Health
28, 224102 (2005).

4.

Andersen, H., Gadeberg, P. C., Brock, B. & Jakobsen, J. Muscular atrophy in diabetic
neuropathy: A stereological magnetic resonance imaging study. Diabetologia 40, 1062–
1069 (1997).

5.

Inzucchi, S. E. & Sherwin, R. S. Type 1 Diabetes Mellitus. Goldman’s Cecil Medicine
(Elsevier Inc., 2011). doi:10.1016/B978-1-4377-1604-7.00561-3

6.

Hurley, B. F., Hanson, E. D. & Sheaff, A. K. Strength training as a countermeasure to
aging muscle and chronic disease. Sport. Med. 41, 289–306 (2011).

7.

Kraschnewski, J. L. et al. Is strength training associated with mortality benefits? A 15 year
cohort study of US older adults. (2016). doi:10.1016/j.ypmed.2016.02.038

8.

Booth, F. W. et al. Waging war on modern chronic diseases: primary prevention through
exercise biology. J. Appl. Physiol. 88, 774–787 (2011).

9.

John Morley, S. E., Baumgartner, R. N., Roubenoff, R., Mayer, J. & Sreekumaran Nair,
K. Sarcopenia. J Lab Clin Med 137, 231–243 (2001).

33

10.

Pedersen, B. K. & Saltin, B. Evidence for prescribing exercise as therapy in chronic
disease. Scand. J. Med. Sci. Sports 16 Suppl 1, 3–63 (2006).

11.

Moy, C. S. et al. Insulin-dependent Diabetes Mellitus , Physical Activity , and Death. 137,
74–81 (1993).

12.

Galassetti, P. & Riddell, M. C. Exercise and type 1 diabetes (T1DM). Compr. Physiol. 3,
1309–36 (2013).

13.

de Ferranti, S. D. et al. Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific
Statement From the American Heart Association and American Diabetes Association.
Diabetes Care 37, 2843–2863 (2014).

14.

Belle, T. L. Van, Coppieters, K. T. & Herrath, M. G. Von. Type 1 Diabetes : Etiology ,
Immunology , and Therapeutic Strategies. Physiol. Rev. 91, 79–118 (2011).

15.

ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 37, 81–90 (2014).

16.

Gillett, M. J. International Expert Committee Report on the Role of the A1C Assay in the
Diagnosis of Diabetes: Diabetes Care 2009; 32(7): 1327–1334. Clin. Biochem. Rev. 30,
197–200 (2009).

17.

Bingley, P. J. Clinical Applications of Diabetes Antibody Testing. J. Clin. Endocrinol.
Metab. 95, 25–33 (2010).

18.

Ziegler, A.-G., Nepom, G. T. & Anette-G Ziegler, M. Prediction and Pathogenesis in Type
1 Diabetes. Immunity 32, 468–478 (2010).

19.

Ziegler, A.-G. & Bonifacio, E. Age-related islet autoantibody incidence in offspring of

34

patients with type 1 diabetes. Diabetologia 55, 1937–1943 (2012).
20.

Perseghin, G. et al. Insulin resistance, intramyocellular lipid content, and plasma
adiponectin in patients with type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 285,
E1174–E1181 (2003).

21.

Schechter, R. & Reutrakul, S. Management of Severe Insulin Resistance in Patients with
Type 1 Diabetes. Curr Diab Rep 55, 76–88 (2015).

22.

Teupe, B. & Bergis, K. Epidemiological evidence for ‘double diabetes’. Lancet 337, 361–
2 (19991).

23.

Gordon-Dseagu, V. L., Shelton, N. & Mindell, J. S. Epidemiological evidence of a
relationship between type-1 diabetes mellitus and cancer: a review of the existing
literature. Int J Cancer 132, 501–508 (2013).

24.

Tuomi, T. What Do They Have in Common? 54, (2005).

25.

Atkinson, M. a & Eisenbarth, G. S. Type 1 diabetes: new perspectives on disease
pathogenesis and treatment. Lancet 358, 221–229 (2001).

26.

Harjutsalo, V. ym. Time trends in the incidence of type 1 diabetes in Finnish children: a
cohort study. Lancet (London, England) 371, 1777–82 (2008).

27.

Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A. & Soltész, G. Incidence trends
for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 200520: a multicentre prospective registration study. Lancet (London, England) 373, 2027–33
(2009).

35

28.

Podar, T. et al. Increasing incidence of childhood-onset type I diabetes in 3 Baltic
countries and Finland 1983-1998. Diabetologia 44 Suppl 3, B17–20 (2001).

29.

Ehehalt, S. et al. Prediction model for the incidence and prevalence of type 1 diabetes in
childhood and adolescence: Evidence for a cohort-dependent increase within the next two
decades in Germany. Pediatr. Diabetes 13, 15–20 (2012).

30.

Karvonen, M. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999.
Diabet. Med. 23, 857–866 (2006).

31.

Krantz, J. S. et al. Early onset of subclinical atherosclerosis in young persons with type 1
diabetes. J. Pediatr. 145, 452–7 (2004).

32.

Greenbaum, C. J. Insulin resistance in type 1 diabetes. Diabetes. Metab. Res. Rev. 18,
192–200 (2002).

33.

Coleman, S. K., Rebalka, I. A., D’Souza, D. M. & Hawke, T. J. Skeletal muscle as a
therapeutic target for delaying type 1 diabetic complications. World J. Diabetes 6, 1323–
1336 (2015).

34.

Krause, M. P., Riddell, M. C. & Hawke, T. J. Effects of type 1 diabetes mellitus on
skeletal muscle: Clinical observations and physiological mechanisms. Pediatr. Diabetes
12, 345–364 (2011).

35.

Andreassen, C. S., Jakobsen, J., Ringgaard, S., Ejskjaer, N. & Andersen, H. Accelerated
atrophy of lower leg and foot muscles-a follow-up study of long-term diabetic
polyneuropathy using magnetic resonance imaging (MRI). Diabetologia 52, 1182–1191
(2009).

36

36.

Andersen, H., Gjerstad, M. D. & Jakobsen, J. Atrophy of foot muscles: A measure of
diabetic neuropathy. Diabetes Care 27, 2382–2385 (2004).

37.

Andersen, H., Schmitz, O. & Nielsen, S. Decreased isometric muscle strength after acute
hyperglycaemia in Type 1 diabetic patients. Diabet. Med. 22, 1401–1407 (2005).

38.

Crowther, G. J. et al. Altered energetic properties in skeletal muscle of men with wellcontrolled insulin-dependent (type 1) diabetes. Am. J. Physiol. Endocrinol. Metab. 284,
E655–E662 (2003).

39.

Fritzsche, K. et al. Metabolic profile and nitric oxide synthase expression of skeletal
muscle fibers are altered in patients with type 1 diabetes. Exp. Clin. Endocrinol. Diabetes
116, 606–13 (2008).

40.

Reske-Nielsen, E., Harmsen, A. & Vorre, P. Ultrastructure of muscle biopsies in recent,
short-term and long-term juvenile diabetes. Acta Neurol Scandinav 55, 345–362 (1977).

41.

Frontera, W. R. & Ochala, J. Skeletal muscle: a brief review of structure and function.
Calcif. Tissue Int. 96, 183–195 (2015).

42.

Hochachka, P. W. Muscles as Molecular and Metabolic Machines. (1994).

43.

Tortora, G. J. & Nielsen, M. T. Principles of Human Anatomy. (2009).

44.

Schiaffino, S. & Reggiani, C. Fiber types in mammalian skeletal muscles. Physiol. Rev.
91, 1447–531 (2011).

45.

Trappe, S. et al. Skeletal muscle signature of a champion sprint runner. J. Appl. Physiol.
118, 1460–1466 (2015).

37

46.

Kohn, T. a, Essén-Gustavsson, B. & Myburgh, K. H. Do skeletal muscle phenotypic
characteristics of Xhosa and Caucasian endurance runners differ when matched for
training and racing distances? J. Appl. Physiol. 103, 932–940 (2007).

47.

Spangenburg, E. E. & Booth, F. W. Molecular regulation of individual skeletal muscle
fibre types. Acta Physiol. Scand. 178, 413–424 (2003).

48.

Peter, J. B., Barnard, R. J., Edgerton, V. R., Gillespie, C. A. & Stempel, K. E. Metabolic
profiles of three fiber types of skeletal muscle in guinea pigs and rabbits. Biochemistry 11,
2627–33 (1972).

49.

Brooke, M. H. & Kaiser, K. K. Muscle fiber types: how many and what kind? Arch.
Neurol. 23, 369–79 (1970).

50.

Essén, B., Jansson, E., Henriksson, J., Taylor, A. W. & Saltin, B. Metabolic characteristics
of fibre types in human skeletal muscle. Acta Physiol. Scand. 95, 153–65 (1975).

51.

Lowry, C. V et al. Enzyme patterns in single human muscle fibers. J. Biol. Chem. 253,
8269–77 (1978).

52.

Spamer, C. & Pette, D. Activity patterns of phosphofructokinase,
glyceraldehydephosphate dehydrogenase, lactate dehydrogenase and malate
dehydrogenase in microdissected fast and slow fibres from rabbit psoas and soleus
muscle. Histochemistry 52, 201–16 (1977).

53.

Reiser, P. J., Moss, R. L., Giulian, G. G. & Greaser, M. L. Shortening velocity in single
fibers from adult rabbit soleus muscles is correlated with myosin heavy chain
composition. J. Biol. Chem. 260, 9077–80 (1985).

38

54.

Staron, R. S. & Pette, D. Correlation between myofibrillar ATPase activity and myosin
heavy chain composition in rabbit muscle fibers. Histochemistry 86, 19–23 (1986).

55.

Schiaffino, S. et al. Three myosin heavy chain isoforms in type 2 skeletal muscle fibres. J.
Muscle Res. Cell Motil. 10, 197–205 (1989).

56.

Bar, A. & Pette, D. Three fast myosin heavy chains in adult rat skeletal muscle. Fed. Eur.
Biochem. Soc. 235, 153–155 (1988).

57.

Termin, A., Staron, R. S. & Pette, D. Myosin heavy chain isoforms in histochemically
defined fiber types of rat muscle. Histochemistry 92, 453–7 (1989).

58.

Smerdu, V., Karsch-Mizrachi, I., Campione, M., Leinwand, L. & Schiaffino, S. Type IIx
myosin heavy chain transcripts are expressed in type IIb fibers of human skeletal muscle.
Am. J. Physiol. 267, C1723–8 (1994).

59.

Pette, D. & Staron, R. S. Myosin isoforms, muscle fiber types, and transitions. Microsc.
Res. Tech. 50, 500–9 (2000).

60.

Talmadge, R. J., Roy, R. R. & Edgerton, V. R. Distribution of myosin heavy chain
isoforms in non-weight-bearing rat soleus muscle fibers. J. Appl. Physiol. 81, 2540–6
(1996).

61.

Caiozzo, V. J. et al. Single-fiber myosin heavy chain polymorphism: how many patterns
and what proportions? Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R570–80
(2003).

62.

Qaisar, R., Bhaskaran, S. & Van Remmen, H. Muscle fiber type diversification during
exercise and regeneration. Free Radic. Biol. Med. 1–13 (2016).

39

doi:10.1016/j.freeradbiomed.2016.03.025
63.

Kleiber, M. Body size and metabolic rate. Physiol. Rev. 27, 511–41 (1947).

64.

Kohn, T. a & Noakes, T. D. Lion (Panthera leo) and caracal (Caracal caracal) type IIx
single muscle fibre force and power exceed that of trained humans. J. Exp. Biol. 216, 960–
9 (2013).

65.

Marx M Charlotte Olsson Lars Larsson, J. O. Scaling of skeletal muscle shortening
velocity in mammals representing a 100,000-fold difference in body size. Pflugers Arch Eur J Physiol 452, 222–230 (2006).

66.

Pellegrino, M. A. et al. Orthologous myosin isoforms and scaling of shortening velocity
with body size in mouse, rat, rabbit and human muscles. J. Physiol. 546, 677–689 (2002).

67.

Edstrom, L. & Kugelberg, E. Histochemical composition, distribution of fibres and
fatiguability of single motor units Anterior tibial muscle of the rat. J. Neurol. Neurosurg.
Psychiat 31, 424–433 (1968).

68.

Henneman, E. The size-principal: a deterministic output emerges from a set of
probabilistic connections. J, exp. Biol 115, 105–112 (1985).

69.

Souayah, N. & Potian, J. Motor unit number estimate as a predictor of motor dysfunction
in an animal model of type 1 diabetes. Am. J. … 602–608 (2009).
doi:10.1152/ajpendo.00245.2009.

70.

Toth, C. et al. Motor unit number estimations are smaller in children with type 1 diabetes
mellitus: A case-cohort study. Muscle and Nerve 50, 593–598 (2014).

40

71.

Gilliver, S. F., Degens, H., Rittweger, J., Sargeant, A. J. & Jones, D. A. Variation in the
determinants of power of chemically skinned human muscle fibres. Exp. Physiol. 94,
1070–8 (2009).

72.

Bottinelli, R., Canepari, M., Pellegrino, M. A. & Reggiani, C. Force-velocity properties of
human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence.
J. Physiol. 495, 573–586 (1996).

73.

Bottinelli, R., Schiaffino, S. & Reggiani, A. C. Force-velocity relations and myosin heavy
chain isoform compositions of skinned fibres from rat skeletal muscle. J. Physiol. 437,
655–672 (1991).

74.

Hyatt, J.-P. K., Roy, R. R., Rugg, S. & Talmadge, R. J. Myosin heavy chain composition
of tiger (Panthera tigris) and cheetah (Acinonyx jubatus) hindlimb muscles. J. Exp. Zool.
A. Ecol. Genet. Physiol. 313, 45–57 (2010).

75.

Malisoux, L., Francaux, M. & Theisen, D. What do single-fiber studies tell us about
exercise training? Med. Sci. Sports Exerc. 39, 1051–1060 (2007).

76.

Miller, M. S., Bedrin, N. G., Ades, P. A., Palmer, B. M. & Toth, M. J. Molecular
determinants of force production in human skeletal muscle fibers: effects of myosin
isoform expression and cross-sectional area. Am. J. Physiol. - Cell Physiol. 308, C473–
C484 (2015).

77.

Seitz, L. B. et al. Relationships between maximal strength, muscle size, and myosin heavy
chain isoform composition and postactivation potentiation. Appl. Physiol. Nutr. Metab. 41,
491–497 (2016).

41

78.

Linari, M. et al. The mechanism of the force response to stretch in human skinned muscle
fibres with different myosin isoforms. J. Physiol. 554, 335–52 (2004).

79.

D ’antona, G. et al. Skeletal muscle hypertrophy and structure and function of skeletal
muscle fibres in male body builders. J Physiol 5703, 611–627 (2006).

80.

Bottinelli, R., Canepari, M., Reggiani, C. & Stienent, G. J. M. Myofibrillar ATPase
activity during isometric contraction and isomyosin composition in rat single skinned
muscle fibres. J. Physiol. 481, (1994).

81.

Han, Y.-S., Geiger, P. C., Cody, M. J., Macken, R. L. & Sieck, G. C. ATP consumption
rate per cross bridge depends on myosin heavy chain isoform. J. Appl. Physiol. 94, 2188–
96 (2003).

82.

Vikstrom, K. L. et al. The vertebrate myosin heavy chain: genetics and assembly
properties. Cell Struct. Funct. 22, 123–129 (1997).

83.

Alberty, R. A. Standard Gibbs free energy, enthalpy, and entropy changes as a function of
pH and pMg for several reactions involving adenosine phosphates. J. Biol. Chem. 244,
3290–302 (1969).

84.

Homsher, E. Muscle enthalpy production and its relationship to actomyosin ATPase.
Annu. Rev. Physiol. 49, 673–90 (1987).

85.

Bangsbo, J. et al. Anaerobic energy production and O2 deficit-debt relationship during
exhaustive exercise in humans. J. Physiol. 422, 539–59 (1990).

86.

Saltin, B. Malleability of the system in overcoming limitations: functional elements. J.
Exp. Biol. 115, 345–54 (1985).

42

87.

Rivero, J. L., Talmadge, R. J. & Edgerton, V. R. Fibre size and metabolic properties of
myosin heavy chain-based fibre types in rat skeletal muscle. J. Muscle Res. Cell Motil. 19,
733–42 (1998).

88.

Behnke, B. J., McDonough, P., Padilla, D. J., Musch, T. I. & Poole, D. C. Oxygen
exchange profile in rat muscles of contrasting fibre types. J. Physiol. 549, 597–605
(2003).

89.

Howald, H., Hoppeler, H., Claassen, H., Mathieu, O. & Straub, R. Influences of endurance
training on the ultrastructural composition of the different muscle fiber types in humans.
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CHAPTER 2
2.1 Introduction:

Type 1 diabetes mellitus (T1DM) is a condition in which a selective destruction of the
insulin producing β-cells of the pancreas results in a loss of insulin production, necessitating
treatment with exogenous insulin in order to control blood glucose levels. The loss of the
pulsatile insulin response that typically counters increases in blood glucose results in chronically
elevated blood glucose, or hyperglycemia, which ultimately leads to microvascular,
macrovascular and neurological complications 1,2. Over time, these complications eventually
manifest in the form of retinopathy, nephropathy, neuropathy, atherosclerotic cardiovascular and
cerebrovascular disease 3. A less studied complication associated with T1DM is diabetic
myopathy, where the skeletal muscle of individuals with T1DM typically exhibit lower muscle
mass, weakness, reduced regenerative and physical capacity as well as a number of hormonal,
metabolic and histopathological alterations 4–12. Another common finding in T1DM is that
glycolytic muscle fibers (MHC IIb, MHC IIx) appear to be more prone to the atrophic effects of
the diabetic milieu compared to oxidative muscle fibers (MHC I, MHC IIa), and often exhibit a
reduced cross-sectional area (CSA) as well as altered metabolic, ultrastructural and regenerative
properties 13–24. Muscle fiber atrophy as well as morphological and ultrastructural abnormalities
have also been observed in recent onset diabetes in humans prior to the administration of insulin
and independent of indications of neuropathy 11,25,26. The effects of diabetes mellitus on the
skeletal muscle of rodents has also been studied extensively, where induction of T1DM has been
primarily achieved through the use of streptozotocin (STZ), a glucosamine-nitrosurea compound
that acts as a powerful alkylating agent methylating the DNA of β-cells resulting in DNA-strand
breaks, cell death and in-turn a loss of insulin production 18,27–30. However, the use of STZ to
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induce T1DM in rodent models of diabetic myopathy is somewhat problematic, as STZ has been
shown to have deleterious effects on muscle mass and muscle fiber size independent of
hypoinsulinemia/hyperglycemia in vivo, and has been shown to impair myoblast proliferation in
a dose-dependent manner in vitro 27. Moreover, the vast majority of STZ-induced T1DM rodent
models to date have utilized a single, high dose (60-70 mg/kg in rats, 120-250 mg/kg in mice)
STZ injection protocol, raising concerns about the myotoxic role of STZ per se, in addition to the
diabetic milieu in the severity of diabetic myopathy progression 13,14,16–19,21,31–35. Furthermore,
the majority of STZ-induced T1DM studies investigating diabetic myopathy have not included
insulin therapy in their experimental design, resulting in hypoinsulinemic/hyperglycemic
extremes that are generally poor representations of the human T1DM population 2,36. Aside from
the likely mortal consequences that extremely low insulin/high blood glucose levels would hold
in humans with T1DM, both hypoinsulinemia and hyperglycemia have independently been
shown to negatively regulate muscle mass, and as such the severity of these factors may limit the
applicability of results from previous rodent models to T1DM patients 11,15,37–40.
Skeletal muscle serves as the body’s primary glucose sink and occupies a central role in
insulin sensitivity. Considering that T1DM predominately arises during adolescence, a period of
significant muscle growth and development, it is important to prevent or treat the progression of
diabetic myopathy at an early age 8,11. Engaging in physical exercise, which is known to induce
profound and varied training adaptations in skeletal muscle, has been proposed as a therapeutic
strategy in the amelioration of the deleterious effects of diabetic myopathy 41,42. However, the
majority of studies investigating the role of exercise (resistance and aerobic endurance) in
humans with T1DM to date have focused primarily on the role of exercise in maintaining healthy
blood glucose levels (i.e. glycated hemoglobin or HbA1C), typically with the aim of preventing
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the development of cardiovascular disease and related complications 43–47. Yet, focusing on
increasing muscle mass in patients with T1DM may afford benefits that extend beyond
improving functional capacity and muscle quality across the lifespan; as skeletal muscle is highly
metabolically active, increased muscle mass may improve insulin sensitivity and glycemic
control. Previous rodent studies have specifically investigated whole-muscle and muscle fiber
hypertrophic capacity in T1DM through the use of synergistic ablation and progressive overload
resistance training protocols 31,33,48,49. While these studies have found that skeletal muscle
maintains a capacity for hypertrophy despite T1DM, the drastic nature of synergistic ablation
induced chronic overload is difficult to compare with the training effects of whole-body
voluntary exercise. Moreover, these studies do not address the muscle fiber-type specific effects
of T1DM or overload in terms of MHC isoforms, considered the best available marker for fiber
type, which is likely necessary to fully understand the fiber-type specific nature of training
adaptations in T1DM 50.
Aerobic endurance training has typically been associated with increases in indices of
oxidative capacity in the skeletal muscle of humans and rodents (i.e. increased mitochondrial
content, oxidative enzymes and capillarization), however, some research has indicated that
aerobic training alone or in conjunction with resistance training can be advantageous in terms of
conferring muscle and fiber hypertrophy as well as preventing T1DM induced muscle atrophy
42,51–56

.Indeed, in human subjects it has been reported that performing a combination aerobic

endurance and resistance training results in greater increases in muscle fiber CSA compared to
resistance training alone 54,55. Conversely, higher intensity resistance exercise may mitigate the
potential for hypoglycemia that is often observed after aerobic endurance training 44,57,58. As
such, characterizing the effects of different modalities of exercise (resistance, aerobic endurance
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and combined) on MHC muscle fiber size is important in order to understand how specific
muscle fiber-types respond to different types of exercise in T1DM. The aim of the present study
was to investigate the role of insulin therapy and exercise modality in maintaining or increasing
muscle fiber CSA in a multiple low-dose STZ, insulin-treated rodent model of T1DM. Firstly,
we hypothesized that intensive insulin therapy (blood glucose 7-9 mmol//l) would result in
superior maintenance of muscle fiber CSA compared to conventional therapy (9-15 mmol/l) in
sedentary animals. Secondly, we hypothesized that exercised animals (resistance, aerobic
endurance or combined) receiving conventional insulin therapy (9-15 mmol/l) would display
increased muscle fiber CSA compared to control and sedentary diabetic animals despite
moderate hyperglycemia, and that animals subjected to resistance/combined training would
display the greatest increases in fiber CSA.
2.2 Materials and Methods:

Ethics approval
The protocols used in the present study were approved by the University Council of
Animal Care of Western University (London, Ontario, Canada) in accordance with the standards
of the Canadian Council on Animal Care (APPENDIX B)
Animals
Thirty-six, 8 week old, male Sprague-Dawley rats were obtained from Charles River
Laboratories (St. Constant, Quebec, Canada). All rats were caged in pairs and held on a constant
12 hour dark/light cycle, temperature (20 ± 1°C) and relative humidity (50%) for the duration of
the study. All rats were allowed access to standard rat chow and water ad libitum.
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Experimental groups
The rats were randomly assigned to one of six treatment groups. The resulting groups
were as follows: control sedentary (CS; n=6), diabetic conventional therapy (DCT; n=7),
diabetic intensive therapy (DIT; n=7), diabetic resistance exercise (DRE; n=7), diabetic high
intensity aerobic exercise (DHE; n=5) and diabetic combined exercise (DCE; n=4). Although all
diabetic groups began with a similar number of animals, severe freeze artifact in some plantaris
muscle samples resulted in the reduced number of animals in DHE and DCE groups.
Experimental Procedures
Diabetes Induction and Insulin Pellet Implantation
After a 5 day acclimatization period following arrival, T1DM was induced in rats through
the use of intraperitoneal (IP), low-dose streptozotocin 20mg/kg (STZ; Sigma-Aldrich) injections
over 5 consecutive days 36,59,60. All STZ injections were dissolved in a 0.1 M citrate buffer (pH
4.5) and performed within five minutes of preparation. The development of T1DM was
confirmed by measures of non-fasted blood glucose (BG) of ≥ 18 mmol/L on two consecutive
days. If necessary, subsequent injections were performed until diabetes was confirmed
(APPENDIX A1). Following confirmation of diabetes, insulin therapy was provided through
surgical implantation of abdominal-subcutaneous insulin pellets (1 pellet; 2U insulin/day;
Linplant, Linshin) (APPENDIX A2). Hyperglycemic range was controlled through adjustment
(addition or removal ±0.5 pellet) of insulin pellets; DCT rats were adjusted to maintain a BG
range of 9-15 mmol/L while DIT rats maintained a BG range of 7-9 mmol/L.
Exercise Training Protocols
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The resistance training protocol used was adapted from Hornerberger and Farrar, and has
been implemented previously in our lab to simulate resistance exercise parameters and
physiological adaptations observed in resistance training in humans 59,61. Following confirmation
of diabetes and insulin pellet implantation, rats were required to climb a ladder (1.1m, 80°) with
weight secured to the proximal portion of the tail contained in a small fabric bag. Familiarization
involved a total of 10 ladder climbs, with progressive increases in weight up to 35% body mass
for 5 days. Following each climb rats were allowed to rest in a dark box on top of the climbing
apparatus for ~2min. Pre-training maximal carrying capacity was determined by initial loading
of 75% body mass, with each subsequent climb adding 30g of weight until animals were unable
to successfully complete the climb. Resistance training took place 5 days per week for 12 weeks.
During training sessions rats were loaded with 50%, 75%, 90% and 100% of pre-determined
maximal carrying capacity performing single climbs, and then completed climbs at 100% until
exhaustion or unwillingness to climb despite pressurized air/tactile stimulation of the haunches.
New maximal carrying capacity was determined every 3 days.
The high-intensity aerobic exercise protocol was one used by our lab to elicit levels of
70-80% of VO2max 59,60,62. Following diabetes confirmation and insulin pellet implantation, rats
were familiarized for 5 days by running for 15 mins on a motorized treadmill by running at
progressively higher speeds up to 30 m/min, 0° grade. Following familiarization, high-intensity
aerobic training involved running for 1 hour at 27 m/min on a 6% gradient, 5 days per week for
12 weeks and motivated to run through the use of pressurized air/tactile stimulation of the
haunches. Combined exercise training involved alternating the aforementioned resistance and
high-intensity aerobic exercise training protocols 5 days per week for 12 weeks, where resistance
training would be performed 3 times one week (high-intensity aerobic exercise 2 times) and
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high-intensity aerobic exercise would be performed 3 times the following week (resistance
training 2 times).
Experimental Measures
Body Weights, Blood Glucose
Body weights (BW) were measured and recorded on a weekly basis throughout the
course of the study. Blood glucose (BG) measurements were made weekly by collecting a blood
droplet (~50 µL) from the manually occluded saphenous vein, and analyzed via the Freestyle
Lite Blood Glucose Monitoring System (Abbot Diabetes Care, Inc.). The corresponding BG
concentration was reported in millimoles per liter (mmol/L).
Tissue Collection, Immunohistochemistry
Rats were sacrificed 72 hours after the last training session by anaesthetization with
isoflurane followed by cardiac exsanguination. The lower limbs were dissected and the plantaris
muscles were removed and wet weight recorded. Plantaris muscles were then mounted in
CryomatrixTM embedding medium (Lot No. 225229, Thermo Fisher Scientific) and rapidly
frozen in isopentane cooled to -70°C by liquid nitrogen. Serial 10µm-thick cryosections were cut
at -20°C with a Leica CM350 Cryostat (Leica Biosystems) and adhered to VWR Superfrost®
Plus Microslides (Cat. No. 48311-703, VWR International). All sections were stored at -30°C
until immunohistochemical analysis.
The immunohistochemical methods used were adapted from previously established
protocols 63,64. Prior to staining, sections were allowed to come to room temperature in a
humidity chamber for ~10 mins. Slides were then washed (5 mins in Tween-PBS, followed by 2
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x 5 mins in PBS) and then incubated in 3% H2O2 for 15 mins at room temperature to quench
endogenous peroxidases. Slides were washed again (Tween-PBS 5 mins, PBS 5 mins) and then
blocked in either 10% (v/v) horse serum with 1% BSA (w/v) in Tween-PBS + Avidin D (Vector
Laboratories, Inc.) (BS-1), or 10% (v/v) goat serum with 1% BSA (w/v) in Tween-PBS +
Avidin-D (BS-2) depending on the primary antibody to be applied (Table). After blocking for 1
hour at room temperature, excess blocking solution was removed from slides and the appropriate
anti-myosin heavy chain primary antibody dilutions in 1% BS-1 or BS-2 and Biotin (Vector
Laboratories, Inc.) of BA-D5, SC-71, 6H1 and BF-F3 were applied to detect MHC I, IIa, IIx and
IIb, respectively (Table 2.1)(Plate 2.1). Slides were then incubated overnight at 4°C. The
monoclonal antibodies BA-D5 and SC-71 were generously donated by C. Putman, while
monoclonal antibodies BF-F3 and 6H1 developed by S. Schiaffino and C. Lucas, respectively,
were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the
NIH and maintained at the University of Iowa, Department of Biology (Iowa City, IA, 52242).
The following day slides were washed again (Tween-PBS 5mins, PBS 5 mins) and secondary
antibody diluted in appropriate blocking solution were applied (Table 2.1). After 1 hour of
incubation at room temperature, slides were washed again (Tween-PBS 5 mins, PBS 5 mins) and
subsequently incubated for 45 mins at room temperature in ABC Peroxidase Staining Kit
solution (Thermo Scientific). Following another wash (Tween-PBS 5 mins, PBS 5 mins) slides
were then developed for 6-8 mins in 3,3’-diaminobenzidine (DAB) (Vector Laboratories, Inc.),
washed in distilled water, dehydrated through graded ethanol washes, and finally cleared with
xylene. Slide coverslips were adhered with toluene-based mounting resin (Krysalon™ Harleco,
EM Science).

72

Primary
Antibody
BA-D5 (MHCI)

Blocking
Solution
BS-1

Dilution

SC-71(MHCIIa)

BS-2

1:10

6H1(MHCIIx)

BS-2

1:10

BF-F3(MHCIIb)

BS-1

1:100

1:20

Secondary
Antibody
biotinylated
horse-anti-mouse
IgG (H+L)
biotinylated
goat-anti-mouse
IgG (H+L)
biotinylated
goat-anti-mouse
IgG (H+L)
biotinylated
horse-anti-mouse
IgG (H+L)

Dilution
1:200

1:200

1:200

1:400

Table 2.1: Primary antibody dilutions, blocking solution, and secondary antibody dilution. BS-1,
BS-2 = blocking solution made with horse and goat serum, respectively.
The antigen specificity of the primary antibodies used was confirmed by the use of an
adjusted metachromatic dye-based myosin ATPase stain originally developed by Ogilvie et al.
and adapted for use in rat muscle by Walsh et al. 65,66. The method consisted of an 8 min
incubation in an acidic (pH 4.4) pre-incubation solution, followed by three 2 min washes in Tris
buffer (pH 7.8). Slides were then incubated for 30 mins in an ATP-incubation solution (pH 9.4),
dipped 4 times in three changes of 1% calcium chloride dihydrate solution and allowed to
incubate for 90s in a 0.1% toluidine blue solution. Slides were then promptly rinsed in running
ddH2O

for 30s, and rapidly dehydrated by 5 dips in 95% ethanol, two sets of 5 dips in 100%

ethanol, and 1 min in xylene. Slide coverslips were adhered with toluene-based mounting resin
(Krysalon™ Harleco, EM Science). (Plate 2.1)
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Microscopy Image Collection and Muscle Fiber Cross-Sectional Area Analysis
All microscopic imaging was performed on a Zeiss Axio Vert.A1 microscope equipped
with an AxioCam ICc 5 camera, linked to the Zen 2.3 Lite computer-based image analysis
program (Carl Zeiss AG). Five distinct regions on each section were captured at 10x
magnification; care was taken to ensure that the same five regions were captured on each of the
MHC stains per animal. Regions were chosen to represent all quadrants and central area of the
muscle.
Muscle fiber cross-sectional areas were measured using Adobe Photoshop® CC (Adobe
Systems). Scale was determined through the use of a 25mm stage micrometer (KR-814) and the
“set measurement scale” option to convert area in pixels to microns squared (μm2). The “quick
selection” tool was then used to record the cross sectional areas of individual muscle fibers and
exported from the “measurement log” as a delimited text file to Microsoft Excel.
Data Analysis
Body weight, blood glucose, plantaris wet weight, and muscle fiber cross-sectional areas
within and between groups were compared using a one-way analysis of variance (ANOVA) with
GraphPad Prism 5 (GraphPad Software, Inc.). On determination of significant differences,
pairwise post-hoc analysis was performed using the Tukey test. Differences were considered
significant at P<0.05. Fiber CSA frequency distributions were generated with GraphPad Prism 5
by taking frequency distribution values for number of fibers per bin size and dividing that
number of fibers by the total fiber number for that specific MHC and group, resulting in
frequency distribution of fiber size expressed as a fractional percentage (i.e. 0.3 = 30%) of total
fiber population.
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2.3 Results:

Physical Characteristics:
Physical characteristics (terminal body weight (g), plantaris whole-muscle weight (mg)
and terminal blood glucose (mmol/l) are presented in Table 2.2. Terminal body weights of all
groups except were similar, except for DIT which was significantly greater than DRE (P< 0.05).
Plantaris whole-muscle weights were not significantly different between any treatment groups
(P>0.05). Although frequent adjustments to the number of implanted insulin pellets were made
over the course of the study in an effort to maintain conventional (9-15mmol/l) and intensive (79mmol/l) blood glucose ranges as closely as possible, terminal blood glucose concentration was
not different between diabetic groups (DCT, DIT, DRE, DHE, DCE), and CS terminal blood
glucose was significantly lower than all diabetic groups (P<0.05). It should be noted that
terminal blood glucose concentrations were determined on unfasted animals. That combined with
the variability in blood glucose range over the conventional and intensive conditions may have
led to the lack of differences.
Resistance Training Load:
Resistance training load over the course of 12 weeks of training for both DRE and DCE
animals is presented in Figure 2.1. Both groups demonstrated significant and near linear
increases in weight carried over the training period.
Fiber Type Percent Composition, Cross-Sectional Area and Cross-Sectional Area Frequency
Distribution:
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Myosin heavy chain fiber type percent composition and mean CSA +- SD, as well as
percent area occupied by the heterogeneous fiber population are presented in Table 2.3.Between
groups, DRE, DHE and DCE MHCIIa/IIx fiber percent composition was significantly greater
than DIT animals (P<0.05). CS and DIT groups displayed significantly greater percent
composition of MHCIIx compared to DCE animals (P<0.05). CS, DCT and DCE animals
display significantly greater MHCIIx/IIb percent composition than DIT animals (p<0.05). In
Figure 2.2, mean fiber CSA +- SE differences are presented within experimental treatment
groups. Within all groups, a general trend of increasing mean fiber CSA occurred from smaller
oxidative fibers to larger glycolytic fibers, and in all groups the mean CSA of MHCIIb fibers
was significantly greater than all fiber types.
Comparisons of mean fiber CSA +- SE between groups and specific fiber type CSA
frequency distributions are presented in Figures 2.3-2.9. CS MHCIIx/IIb fibers were significantly
larger than DCT MHCIIx/IIb fibers (P<0.05). DIT animals exhibited MHCIIa and IIa/IIx CSA’s
that were significantly larger than all other treatment groups (P<0.05), MHCIIx CSA that was
greater (P<0.05) than CS, DCT and DHE, and MHC IIx/IIb as well as MHCIIb CSA’s that were
greater (P<0.05) than CS and DCT animals. DRE animals displayed MHCIIa CSA that was
greater (P<0.05) than DHE, MHCIIa/IIx that was greater (P<0.05) than CS, DCT and DHE,
MHCIIx CSA that was greater (P<0.05) than CS, DCT, DIT and DHE groups, as well as
MHCIIx/IIb and MHCIIb CSA’s that were greater (P<0.05) than CS and DCT treatment groups.
DHE animals exhibited MHCIIx/IIb fiber CSA that was greater (P<0.05) than DCT and MHCIIb
CSA that was greater (P<0.05) than CS and DCT treatment groups. DCE animals displayed
MHCI/IIa CSA that was greater (P<0.05) than CS, DCT and DIT animals, although these fibers
were very few in number. DCE animals also exhibited MHCIIa CSA that was greater (P<0.05)
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than DCT and DHE, MHCIIa/IIx CSA greater (P<0.05) than CS, DCT and DHE, MHCIIx CSA
greater (P<0.05) than CS, DCT and DHE, MHCIIx/IIb CSA greater (P<0.05) than CS and DCT
and MHCIIb CSA that was significantly larger (P<0.05) than all other treatment groups.

Group

CS (n=6)

DCT (n=7)

DIT (n=7)

DRE (n=7)

DHE (n=5) DCE (n=4)

Terminal

613.0 ±

560.0 ±

621.1* ±

519.7 ±

513.2 ±

536.5 ±

BW (g)

83.2

69.7

45.8

56.1

51.6

54.6

Plantaris

547. 9 ±

546.5 ±

609.6 ±

521.6 ±

570.7 ±

522.3 ±

Wt. (mg)

72.7

88.3

73.5

47.3

55.8

55.1

Terminal

3.983** ±

16.43 ±

11.81 ±

12.40 ±

15.54 ±

16.93 ±

BG

0.3

1.9

3.6

5.2

1.3

2.1

(mmol/l)

Table 2.2: Physical characteristics for experimental treatment groups. All data presented as
mean ± SD. *=sig. > DRE. ** = sig. < all other groups.
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Resistance Training Load
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Figure 2.1: Mean maximal resistance training load for DRE and DCE groups over course of 12
weeks of training. All data points expressed as mean ± SE.
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Condition

CS
n = 3234

MHCI

267
8.26
2784
± 831.6
6.96

1004
31.04
3306
±888.7
29.46

501
15.49
4216
±1264
18.52

569
17.59
4489
±1190
24.47

39
1.29
2211
±636.2
0.87

566
18.77
2420
±759.1
13.44

172
5.7
2907
±705.1
4.90

798
26.46
3340
±997.5
26.16

424
14.06
3740
±1044
15.56

759
25.17
4330
±1263
32.30

±1161

15
0.52
2201
±572.2

788
27.28
2792
±897.5

33
1.14
4296
±933.3

879
30.44
3633
±1024

104
3.60
4657
±1159

763
26.42
5034
±1606

8.38

0.3

20.5

1.31

29.54

4.43

35.54

66
2.26
2643
±817.5
1.57

532
18.22
2540
±828.9
12.16

350
11.99
3298
±1229
10.37

780
26.71
3821
±1257
26.82

259
8.87
4657
±1491
10.91

655
22.43
5229
±1420
30.87

13
.66
2940
±638.7
.56

483
24.33
2325
±646.9
16.37

317
15.7
2893
±989.2
13.14

413
20.81
3201
±1332
19.35

208
10.48
4394
±1596
13.42

384
19.34
5280
±1748
29.92

32

318

371

192

257

317

1.95

19.38

22.61

11.7

15.67

19.32

40.23

3117
±1034
3.03

2574
±824.9
12.84

3219
±1158
18.67

3654
±1136
10.93

4689
±1655
18.8

6161
±1481
30.56

40.5

±830.4
6.78

±893.6
7.48

±1151
7.3

167
#
8.41
%
cross 2941

%
area
DCE
n = 1641

610
18.86
2439
±687.6
13.5

278
#
9.52
%
cross 2920

%
area
DHE
n = 1985

16
0.49
2215
±581.7
0.3

306
#
10.6
%
cross 2889

%
area
DRE
n = 2920

MHCIIb %
Hybrid

258
#
8.55
%
cross 2930

%
area
DIT
n = 2888

MHCIIa MHCIIa MHCIIx MHCIIx
/IIx
/IIb

267
#
8.26
%
cross 2757

%
area
DC
n = 3016

MHCI
/IIa

±866.9
7.24

154
#
%
9.38
cross 2748

%
area

±703.8
6.65

24.24

25.78

21.05

21.33

4.26

6.04

23.12

22.85

26.84

27.12
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Table 2.3: Total fiber number, percent fiber composition, fiber CSA and percent area occupied
by fiber population. All fiber CSA values are reported as mean ± SD.
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A

C

Myosin ATPase

B

MHCIIa (SC-71)

D

E

MHCIIb (BF-F3)

MHCI (BA-D5)

MHCIIx (6H1)
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Plate 2.1: Representative images of fiber types in a trained diabetic rat which underwent
resistance training with I = fibers expressing only MHCI, IIa = fibers expressing only MHCIIa,
IIx = fibers expressing only MHCIIb, IIB = fibers expressing only MHCIIb. IIa/IIx and IIx/IIb
fibers expressing both IIa/IIx MHC’s and IIx/IIb MHC’s respectively. A) metachromatic myosin
ATPase. B) BA-D5 antibody specific to MHCI. C) SC-71 antibody specific to MHCIIa. D) 6H1
antibody specific to MHCIIx. E) BF-F3 antibody specific to MHCIIb.
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Figure 2.2: MHC fiber CSA differences within groups. All data presented as mean ± SD.
Differences were considered were considered significant where P<0.05.
* = sig. > MHCIIa, ** = sig. > MHCI/IIa, MHCIIa, *** = sig. > MHCI/IIa, MHCIIa,
MHCIIa/IIx, α = sig. > MHCI, λ= sig. > MHCIIx, Ω = sig. > all MHC. Exceptions where DIT
MHCIIa is only sig. > MHCI/IIa, DHE MHCIIx only sig. > MHC IIa, MHC IIa/IIx and DCE
where MHCIIx only sig. > MHCI, MHCIIa and MHCIIa/IIx.
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Figure 2.3: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCI. A) MHCI CSA differences between groups, data expressed as mean ± SD, no statistically
significant differences. B – H) Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE
and DCE groups.

0.0

CSA (m2)

5500

CSA (m2)

DHE MHCI-IIa

H

0.2

0.0

CSA (m2)
5000
5500

3500

3000

5500

0.2

5000

0.4

4500

0.6

4000

DCE MHCI-IIa

4500

CSA (m2)

4000

3500

0.6
0.0

3000

0.2

2500

0.6

F

2500

CSA (m2)

2000

DIT MHCI-IIa
0.0

1500

5500

5000

4500

4000

3500

3000

2500

2000

1500

0.2

2000

0.6

D

1500

CS MHCI-IIa

500

0.0

1000

DCE

500

0

1000

500

5500

5000

4500

4000

3500

3000

2500

2000

1500

1000

1000

500

2000

1000

3000

0

4000

Fractional Frequency

B

0

0.4

Fractional Frequency

***

0

0.4

Fractional Frequency

5500

5000

4500

4000

MHC I/IIa Hybrids

0

0.4

Fractional Frequency

5500

5000

4500

3500

DHE

5000

4500

4000

3500

3000

2500
DRE

4000

3500

3000

2500

2000

1500
DIT

3000

2500

2000

1500

1000
DCT

2000

1000

0

µm2

A

1500

G
500

Fractional Frequency

CS

1000

0.0

0

E

500

0.0

0

Fractional Frequency

C

500

Fractional Frequency

86

MHCI-IIa Hybrid Fiber Size Distribution
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Figure 2.4: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCI/IIa A) MHCI/IIa CSA differences between groups, data expressed as mean ± SD. B-H)
Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. *** = sig. >
CS, DCT, DIT.
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Figure 2.5: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCIIa A) MHCIIa CSA differences between groups, data expressed as mean ± SD. B-H) Fiber
CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. * = sig.> DCT, λ=
sig. > DHE, Ω = sig. > all groups.
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Figure 2.6: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCIIa/IIx A) MHCIIa/IIx CSA differences between groups, data expressed as mean ± SD. BH) Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. ** = sig.
> CS, DCT, λ= sig. > DHE, Ω = sig. > all groups.
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Figure 2.7: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCIIx A) MHCIIx CSA differences between groups, data expressed as mean ± SD. B-H) Fiber
CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. ** = sig. > CS,
DCT, *** = sig. > CS, DCT, DIT, λ= sig. > DHE
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MHCIIx-IIb Hybrid Fiber Size Distribution
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Figure 2.8: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCIIx/IIb A) MHCIIx/IIb CSA differences between groups, data expressed as mean ± SD. BH) Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. * = sig.>
DCT, ** = sig. > CS, DCT.

G

0.00

CSA (m2)

6000

4000

2000

0
0.00

CS MHCIIb

0.20

DIT MHCIIb

0.20

DHE MHCIIb

0.15

0.10

0.05

D

0.20

0.10

0.05

0.00

CSA (m2)

F

0.10

0.05

0.00

CSA (m2)

H

0.00

0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

**
Fractional Frequency



0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

0.15

Fractional Frequency

8000

DCE

**

DHE

**

DRE

DIT

DCT

CS

µm2

MHCIIb CSA

0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

0.15

Fractional Frequency

Fractional Frequency

A

0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

0.00

Fractional Frequency

E
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

0.00

0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

Fractional Frequency

C

0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
10000
10500
11000
11500
12000

Fractional Frequency

96

B
0.20

MHCIIb Fiber Size Distribution

0.15

0.10

CS
DCT
DIT
DRE
DHE
DCE

0.05

CSA (m2)

0.20

DCT MHCIIb

0.15

0.10

0.05

CSA (m2)

0.20

DRE MHCIIb

0.15

0.10

0.05

CSA (m2)

0.20

DCE MHCIIb

0.15

0.10

0.05

CSA (m2)

97

Figure 2.9: MHC CSA differences between groups and fiber CSA frequency distributions for
MHCIIb A) MHCIIb CSA differences between groups, data expressed as mean ± SD. B-H) Fiber
CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. ** = sig. > CS,
DCT, Ω = sig. > all groups.
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2.4 Discussion:

The present study demonstrated that both exercise modality and intensity of insulin
therapy induce differential effects on the cross-sectional area (CSA) of muscle fibers identified
by myosin heavy chain in multiple low-dose STZ-diabetic, insulin treated rats. Furthermore, this
study provided support for the protective effect of both exercise and insulin in the attenuation of
the reduced body weight, whole-muscle weight and glycolytic muscle fiber size commonly
observed in diabetic myopathy 8,11,13,67. Although several studies have examined the effects of
T1DM and STZ-induced T1DM on skeletal muscle in both humans and rodents, there is a
paucity of research examining the long-term effects of different types of exercise training and
insulin therapy regimens on the CSA of muscle fibers identified specifically by their MHC
content. As muscle fibers expressing different MHC display differential sensitivity to various
atrophic stimuli, analyzing fiber size in the context of each of the four MHC’s (as well as
“hybrid” fibers co-expressing MHC’s) in the present model of T1DM has allowed for a
characterization of how these fibers respond to exercise and insulin therapy in a diabetic milieu
23

. In addition, studies utilizing STZ to induce the development of T1DM have been considered

contentious in regards to diabetic myopathy, as often, the dose of STZ administered has been
shown to have atrophic and metabolic effects on muscle fibers independent of hyperglycemia
27,36,68,69

. Hence, a multiple low-dose STZ injection protocol was used to induce T1DM in the

present study in an attempt to restrict the atrophic effects of STZ per se as opposed to
hyperglycemia and/or hypoinsulinemia associated with T1DM. Further, like many rodents
studies of STZ induced T1DM, subcutaneously implanted insulin pellets and specific blood
glucose range clamps were employed in an attempt to provide a more realistic model of the
average T1DM human population 70. The use of an appropriate insulin supplemented STZ
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model, reminiscent of human T1DM, largely maintained body mass, and muscle fiber size
despite chronic, moderate hyperglycemia. All of the exercise models employed in the present
study appeared, at minimum, to maintain muscle fiber size (aerobic endurance) or result in
increased fiber CSA (resistance, combined). Exercise did differentially influence both muscle
fiber composition and fiber size of specific fiber types, however, collectively, the use of multiple
low-dose STZ induction of T1DM, efforts to control blood glucose in physiologically relevant
ranges via insulin supplementation, long term exercise training, and IHC identification and
analysis of MHC specific fiber CSA have afforded novel insights into the muscle fiber specific
nature of diabetic myopathy.
A common finding in many STZ induced T1DM rodent models investigating diabetic
myopathy are physical characteristics including significantly reduced body weight and wholemuscle weight in diabetic animals compared to non-diabetic controls 11,14–16,18,20,22,31,34,71. In the
present study, the finding that mean terminal body weight and whole-muscle plantaris weight in
all groups were not significantly different from one another (except for where DRE body weight
was significantly smaller than DIT) is likely due to a number of different factors including the
nature of the experimental design (STZ dose, insulin treatment, blood glucose levels), musclespecific factors (muscle glycogen and lipid levels, H2O content) and exercise training. Unlike the
present study, the majority of previous STZ T1DM rodent models reporting significantly reduced
body and whole-muscle weight in diabetic animals tend to have utilized a single, high-dose STZ
injection, typically between 60-70 mg/kg in rats and 120-250 mg/kg in mice 13,14,16,18,21,22,31–34,71–
73

. As previously mentioned, STZ has been shown to exhibit negative effects on skeletal muscle

growth and development independent of the resultant hyperglycemia and/or hypoinsulinemia that
follows STZ-induced pancreatic β-cell apoptosis. Johnston et al. examined these muscle-specific
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effects of STZ in vivo and in vitro using young Sprague-Dawley rats and C2C12 myoblasts,
respectively and the changes were determined to be dose-dependent in nature and due to a G2/M
phase cell cycle arrest

27

. As the repair of DNA damage primarily occurs during the G2 phase

prior to entering the M (mitotic) phase of the cell cycle, and STZ treatment is generally
understood to cause DNA alkylation through an increase of free radicals and ROS, the G2/M
phase cell cycle arrest observed in vitro was suggested to support the idea that STZ exposure
induces significant DNA damage in myoblasts 27. Hence, the multiple, low-dose STZ (20mg/kg)
model employed in the present study may have played a role in the relative maintenance of body
and whole-muscle weight observed treatments by reducing the dose-dependent myotoxic effects
of STZ in all of all of the experimental treatment groups. It should be noted, however, that STZ
transportation relies on the presence of the glucose transporter isoform GLUT2, which although
largely expressed in the liver and pancreas has been shown to be expressed only in small
quantities in skeletal muscle, and thus may actually indicate a limited capacity of STZ for
myotoxicity However, as measured, the terminal body weights of the animals in the present
experiment did not allow for distinguishing between the relative contributions of lean body mass
(i.e. muscle) versus fat mass. Body composition analysis would have been helpful in this regard,
as observation suggested that DIT animals had significantly more abdominal fat (as has been
observed in intensively treated human subjects) than their exercise trained counterparts.
Most studies using STZ to assess the effect of T1DM on muscle mass have reported
reduced whole-muscle weight and a preferential atrophy of glycolytic muscles/fibers. However,
they have neglected to control blood glucose through insulin supplementation, and as such the
blood glucose concentrations exhibited by these animals are far greater than would be observed
in most human patients with T1DM 36. Blood glucose concentrations throughout the course of
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experimentation or at the time of sacrifice, ranged anywhere from 20 mmol/l to 38.8 mmol/l,
with some studies reporting blood glucose levels as high as 44.4 and 56.5 mmol/l 13,14,16,18–
21,31,33,34,74

. In the present study, effort to clamp blood glucose ranges (7-9 mmol/l for intensive,

9-15 mmol/l for conventional therapy and exercised groups ) was used in order to model both the
tightly regulated/monitored and moderately hyperglycemic conditions that are more
representative of the general human population living with T1DM 36,70. The disparity between
blood glucose levels typically observed in humans with T1DM and those reported in rodent
models of diabetic myopathy is an important consideration as hyperglycemia per se has been
shown to have deleterious effects on skeletal muscle. Krause et al. have indicated that some of
the negative outcomes of hyperglycemia related to the diabetic myopathic condition and negative
regulation of muscle mass likely includes the formation of advanced glycation end products
(AGE), chronic oxidative stress, and the polyol pathway 11. Hypoinsulinemia per se is also a key
contributor alongside hyperglycemia to diabetic myopathy. Humans and animals with T1DM
that are not subjected to insulin treatment develop a catabolic state where the rate of protein
catabolism exceeds the rate of protein synthesis, and in turn results in a net loss of protein that is
especially evident in skeletal muscle 75. Hence, the use of intensive and conventional insulin
therapy treatment for sedentary and exercised diabetic animals in the present study was also
likely a significant contributor to the maintenance of body and whole-muscle weight as well as
fiber CSA that was observed in all groups. The effects of insulin treatment on skeletal muscle
mass in T1DM have been determined to be due primarily to an anti-catabolic effect in the
reduction of muscle protein breakdown as opposed to an increase in muscle protein synthesis
39,76

. Significant inhibition of muscle protein catabolism can be induced by even minute

increases in circulating insulin concentration (i.e. to 104.2 pmol/l), whereas increases in insulin
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within postprandial ranges does not exert an increase in muscle protein synthesis. The important
role of insulin supplementation in the maintenance of skeletal muscle mass has been
investigated, the results of which are especially pertinent to the present study. The investigators
used both low multiple-dose (45 mg/kg x 5 days, IP) and single high-dose (180 mg/kg, IP) STZ
injections for comparison

40

. Mice subjected to multiple-dose STZ exhibited a reduction in body

weight (13%) and 1.88 fold increase in myostatin (MSTN) compared to controls, while highdose mice exhibited a severe reduction in body weight (27%) and a 3.7 fold increase in MSTN,
likely indicating a role of MSTN expression and severity of muscle atrophy 40. As a growth and
differentiation factor, MSTN is known as a potent negative regulator of muscle mass in humans
and animals, and MSTN inhibition has been shown to increase muscle mass, fiber size, insulin
sensitivity, p-Akt expression and GLUT4 expression, improve muscle regeneration and reduce
atrophy 77–85. Of particular significance is that treatment of the multiple-dose STZ animals with
insulin after 2 weeks of diabetes (4IU/day x 3 days, subcutaneous injection) not only corrected
hyperglycemia and loss in body weight but completely ameliorated the increased MSTN and
atrogin-1 expression 40. Not only does this suggest that diabetes in the absence of insulin, even
using a multiple low-dose STZ protocol can significantly reduce body weight and upregulate
MSTN and atrogin-1; but that insulin treatment can completely “reverse” these atrophic indices.
Another recent rodent study has suggested the use of MSTN inhibition as an adjuvant therapy in
treating T1DM, after finding that in addition to prevention of muscle loss, MSTN mRNA
reduction led to increases in insulin sensitivity as well as increases in GLUT4 expression which
led to significant improvement in blood glucose regulation 85. Hence, it is possible that the
maintenance of body weight, muscle mass and fiber CSA may be partially due to the role of
insulin treatment in attenuating MSTN expression as well as preventing a net protein catabolism
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of skeletal muscle from taking place.
Insulin treatment in DCT, DIT and exercised animals (DRE, DHE, DCE) was also
essential for controlling blood glucose levels and thus reducing the negative effects of
hyperglycemia on skeletal muscle mass. We had hypothesized that intensive insulin therapy
(blood glucose 7-9 mmol//l) would result in superior maintenance of muscle fiber CSA
compared to conventional therapy (9-15 mmol/l) in sedentary animals. We based this upon the
known effects of hyperglycemia, including an acceleration of the process of glycation resulting
in the formation of cross-linkages between proteins known as advanced glycation end products
(AGE) 86,87. AGE accumulation in both serum and muscle has been associated with reducing
motor function and grip strength in non-diabetic elderly individuals 1,86,88–91. In T1DM muscle,
AGE accumulation is most evident in fast fibers which are also the most affected by diabetic
myopathy 90,92,93. In addition, hyperglycemia is also associated with elevated ROS and activation
of the polyol pathway, both of which may contribute to diabetic myopathy The fact that both
DCT and DIT were relatively unaffected by differences in hyperglycemia compared to CS
further suggests that the presence of insulin may override the negative impact of hyperglycemia
on skeletal muscle, at least in the short term. As expected, intensive insulin therapy permitted the
same benefits that conventional insulin therapy conferred in maintaining body weight, wholemuscle weight and fiber CSA compared to healthy controls. However, the present data seem to
indicate that treatment with an increased dose of insulin may have differential effects on specific
MHC fiber types in sedentary rodents despite the reported role of insulin only increasing muscle
protein synthesis in the presence of elevated amino acid levels 39,76. Although maintained or
improved CSA compared to DCT animals was expected in DIT animals, the observation that
mean MHC IIa fiber CSA was significantly larger than all other conditions including exercise
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was surprising. As food and water were provided ad libitum, it is possible that DIT animals may
have engaged in hyperphagia, elevating circulating amino acid levels and thus increasing the rate
of muscle protein synthesis in conjunction with reducing the rate of muscle protein breakdown.
However, the finding that DIT MHC IIa/IIx fibers are also significantly larger than all other
conditions and exhibit a frequency distribution that appears somewhat bimodal and is noticeably
right-shifted seems to indicate that a transition from MHC IIx to IIa is responsible for the robust
increase in DIT MHC IIa CSA and the slightly higher MHC IIa percent composition.
Interestingly, DIT animals also exhibited far fewer hybrid fibers than any other group (Table
2.2). This could indicate that elevated insulin levels “lock in” single phenotype fibers or that any
fiber type transitions resulting from insulin supplementation are complete by the end of 12
weeks.
The present study’s investigation of fiber type percent composition in plantaris also
provided insight into the fiber specific effects of diabetic myopathy. In general, all groups
maintained similar percent composition of specific fiber types as has been previously observed
in healthy rat plantaris muscle, where slow oxidative (MHCI) fibers occupy ~10% of the fiber
population and fast oxidative glycolytic and fast glycolytic (MHC IIa, MHCIIx and MHC IIb)
make up the remaining 90% of the fiber population 95.This is in agreement with previous studies
13,18

. However, both exercise and insulin supplementation appeared to differentially influence

muscle fiber proportions particularly within the MHCIIx fibers (Table 2.2). The composition of
the more oxidative MHCI and MHCIIa were largely unaltered by diabetes, with or without
exercise, probably as a consequence of the presence of insulin and the fact that they are
frequently recruited. In rodents, resistance training has been shown to result in increases in the
expression of MHCIIx fibers, whereas aerobic endurance training generally increases the percent
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composition of MHCIIa and MHCI fibers 96. In the present study, all exercise conditions
exhibited significantly elevated proportions of hybrid IIa/IIx fibers suggesting that both
resistance and aerobic exercise tended to generate fiber type transitions. In fact, more than 20%
of muscle fibers assessed in the DCE group were MHCIIa/IIx hybrids and DCE also had
significantly fewer MHCIIx fibers than CS or DIT. These data suggest that both DHE and DCE
groups may be driving less aerobic MHCIIx to more aerobic fibers expressing MHCIIa. The
picture is less clear with the DRE resistance exercise condition but given a high proportion of
MHCIIa/IIx (over 20%) and the observation of 2 distinct peaks of cross-sectional area in these
hybrids (Fig 2.6) it also appears that the resistance training employed in the present study may
also transition MHCIIx to MHCIIa fibers. The DIT group which experienced the greatest insulin
supplementation in contrast had very few hybrid fibers. As noted above, the reason for this is
uncertain but may be associated with the degree of insulin supplementation. In CS and DIT
animals, the relative percent composition of MHCIIx fibers was significantly higher than that of
DCE animals, MHCIIx/IIb percent composition was significantly higher in CS and DCT animals
compared to DIT. This is expected in comparison to the exercise conditions due to a reduced
neural influence of physical activity 23,96,97. Furthermore, in humans, increases in the percent
composition of glycolytic fibers has been observed in the skeletal muscle of men with wellcontrolled T1DM 9,11. It has been proposed that periodic influxes of glucose in response to
insulin treatment could result in the expression of glycolytic muscle fiber genes and drive this
increased relative expression, which may explain the observations in DIT animals due to their
intensive insulin therapy 11.
The effects of different intensities of insulin therapy and exercise modality on the CSA of
the heterogeneous fiber population in the present study also provided several interesting insights.
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Within groups and in agreement with previous research, muscle fibers showed a gradual increase
in CSA moving from more oxidative fibers to more glycolytic fibers, where MHCIIb fibers had
the largest CSA of all fiber types 13,50,95,98.
The effects of diabetes and exercise became more apparent when the CSA of different
fiber types was compared between groups. Fibers expressing MHCI appeared to be unaffected by
either diabetes or exercise. An expected finding, as MHCI has been consistently reported to be
resistant to the atrophy induced by T1DM 11,18,23. Surprisingly, diabetes did not result in any loss
of fiber CSA when compared to control animals. Prior research had suggested that fast-twitch,
particularly MHCIIx and MHCIIb fibers might be particularly sensitive to diabetes resulting in
reduced CSA 8,11,13,15,16,74,99. The fact that no changes were observed in the present study suggests
that even a minimum amount of insulin is able to maintain fiber size and reduce atrophy. It was
hypothesized that intensive insulin therapy (DIT) would provide superior maintenance of fiber
CSA compared to conventional therapy (DCT). This hypothesis was supported but it was
surprising that for faster fiber types, DIT CSA were actually greater than both the conventional
diabetic group (DCT) and the control (CS). This was particularly evident for MHCIIa fibers,
where the average CSA for DIT fibers was greater than any other group and these animals also
exhibited some of the largest MHCIIa fibers (Fig 2.5). Although the n is small (33 fibers), an
examination of MHCIIa/IIx hybrids also reveals higher average fiber sizes for DIT as well as
two populations of fiber sizes which might suggest that transitions are occurring. As the anabolic
effects of insulin treatment are known to primarily be limited to attenuating muscle protein
breakdown, these increases in fiber hypertrophy beyond control and exercised animals is
somewhat perplexing 39. However, as elevated levels of amino acids in conjunction with insulin
have been shown to increase the rate of muscle protein synthesis, it is possible that DIT animals
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engaged in hyperphagia, thus driving the increased fiber CSA observed 39,100. Perhaps fibers
expressing MHCIIa are particularly sensitive to insulin, although other studies have reported that
fibers expressing MHCI to have the greatest insulin responsiveness
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.The greatly reduced

number of hybrid fibers co-expressing MHC’s in DIT animals is another surprising finding, and
in conjunction with DIT’s effect on CSA warrant further investigation.
Exercise also induced significant and varied changes in CSA in the heterogeneous fiber
population of diabetic animals. Overall, DHE animals essentially maintained muscle fiber CSA
while DRE and DCE animals exhibited significant increases in the CSA of specific glycolytic
fiber populations. Aerobic endurance exercise has typically been shown to induce increases in
oxidative fibers in non-diabetic rodents and humans (MHCI, MHCIIa, respectively) and even
result in MHCI and MHCIIa fiber hypertrophy 51,53,96. Although hypertrophy of these fiber types
was not evident in the present study, the reduced MHCIIa CSA when compared to other exercise
conditions (Fig 2.5A), coupled with the trend toward higher MHCI/IIa hybrid fiber CSA (Fig
2.4A) and presence of some large MHCI fibers (Fig 2.3G) suggests that perhaps the intensive
aerobic exercise of DHE is driving muscle fibers to a more oxidative phenotype. DHE animals
also displayed an increase in MHCIIb fiber CSA compared to DCT animals which may have
been due to recruitment of these larger glycolytic fibers during the intense aerobic exercise
sufficient to induce fiber growth.
As expected, animals that underwent resistance training displayed pronounced increases
in the CSA of glycolytic fibers (MHCIIa/IIx – MHCIIb – Figs 2.6-2.9), which is consistent with
previous research on resistance training induced fiber hypertrophy adaptations 102. These
increases in fiber CSA occurred independently of whole-muscle hypertrophy. However, the lack
of gross hypertrophy in the plantaris muscle of DRE and DCE rats in the present study is
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supported by previous research using the same resistance training protocol, where only flexor
hallucis longus (FHL) muscle showed signs of gross hypertrophy 61. Both conditions which
incorporated resistance training exhibited significantly larger type II fibers, with the exception of
MHCIIb fibers, compared to DHE. This could be partially a function of the additional load
placed on these fibers during weight lifting or perhaps the smaller MHCIIa-MHCIIx fibers
observed in DHE may reflect an adaptation where a reduced diffusion distance is critical 103,104.
These differences were particularly evident in the MHCIIa fiber population as even the largest
fibers in the DHE tended to exhibit a smaller CSA than in the other conditions (Fig 2.5). An
examination of the range of CSA for MHCIIx fibers in the conditions which incorporated high
intensity running (Fig 2.7G and H) reveals three peaks in fiber size. Although speculative, it is
possible that this is further evidence of muscle fiber type transition. Another interesting
observation was that the combined exercise group DCE exhibited the largest MHCIIb fibers (Fig
2.9), despite lifting weight only half as often as DRE. Indeed, as noted above, even the MHCIIb
fibers in DHE were similar in size to those in DRE. Both DRE and DCE animals carried similar
and progressively heavier loads over the course of the study. However, it is possible that this
discrepancy may be due to the fact that DRE animals trained 5 days a week, whereas DCE
animals alternated between daily aerobic endurance and resistance training. This may have
permitted greater time for muscle recovery between bouts of resistance training. Previous
research investigating the effect of “over-training” in resistance trained rats has reported findings
that support this notion 105. In that study, rats performed a progressive “jumping” resistance
training protocol over the course of 12 weeks, increasing from 60% to 85% of body weight
overload, which was reported to be about 15% greater than recommended for inducing muscle
hypertrophy 105. Resistance training was performed 5 days per week in order to limit recovery
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time between bouts of exercise. Following 12 weeks of training, exercised rats showed decreased
body weight and significantly reduced plantaris muscle fiber CSA. The maintenance and
hypertrophy of muscle fibers in DCE animals seems to indicate that combined exercise training
may be the superior exercise modality of choice for skeletal muscle benefits in T1DM. Not only
does exercise potentially increase insulin sensitivity, improving glycemic control - reducing the
risk of cardiovascular disease, it is possible that when performed concurrently with resistance
training as in DCE animals endurance training may also increase muscle mass while reducing the
risk of late onset hypoglycemia 44–46,59. It should be noted, however, that as endurance and
resistance exercise training drive the expression of diverse adaptive gene programs, the concept
of an “interference effect” whereby combined training results in compromised adaptations has
been postulated 42.In human studies of concurrent exercise training, evidence to support the
notion of concurrent exercise training having superior effects on muscle fiber size has been
reported. In one study, 5 weeks of combined resistance and endurance training in humans was
shown to induce greater increases in vastus lateralis muscle fiber CSA (17% versus 9%) than
resistance training alone, indicating that combined training does not appear to hinder but may
actually improve the hypertrophic response of muscle fibers 54. Ultimately, the fiber CSA results
of the present study indicate that combined exercise training results in the greatest benefit in
terms of muscle hypertrophy, and that the benefits of exercise of any modality in terms of fiber
CSA are similar to those observed in intensively treated animals, despite exercised animals
having moderate hyperglycemia. Furthermore, the varied effects of insulin treatment and
exercise modality on the size of specific muscle fibers in the heterogeneous fiber population
observed in the present study warrant further investigation, where identifying the molecular
mechanisms underlying the myriad of fiber adaptations at present will help to further
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characterize the means by which these fiber size differences occur.
2.5 Conclusion:

The deleterious effects of T1DM on skeletal muscle mass and function, collectively
termed diabetic myopathy, has been reported to result in a preferential atrophy of glycolytic
muscle fibers compared to oxidative fibers. As T1DM typically develops during adolescence, a
time of significant skeletal muscle growth and development, early intervention in preventing or
treating the development of these negative effects of the diabetic milieu on skeletal muscle may
prove important in maintaining healthy skeletal muscle mass across the lifespan. However, the
current body of research regarding diabetic myopathy’s fiber-specific atrophic effects has been
primarily conducted through the use of rodent models of T1DM that are poorly representative of
the human T1DM population due to extreme levels of hyperglycemia and/or hypoinsulinemia as
well as high doses of myotoxic STZ to induce β-cell destruction. Moreover, despite the known
beneficial effects of exercise on skeletal muscle, few studies have been conducted on the effects
of exercise on muscle fiber size in T1DM, and fewer still have compared the effects of different
exercise modalities on the heterogeneous fiber population. The aim of the present study was to
investigate the effects of conventional insulin therapy (DCT; blood glucose 9-15 mmol/l), which
is more representative of the general T1DM population, compared to intensive insulin therapy
(DIT; 7-9mmol/l) and different long-term exercise training modalities (DRE, DHE, DCE;
resistance, aerobic endurance and combined, respectively) on the CSA of MHC-specific muscle
fibers 36,70. The findings reported presently have afforded insight into how muscle fibers are
differentially affected by these conditions while utilizing a model STZ-induced T1DM that
maintains translational capacity to humans with T1DM through the incorporation of
subcutaneous insulin pellet treatment and specific blood glucoses ranges.
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The maintenance of body weight and whole-muscle weight in diabetic animals (sedentary
and exercised) compared to non-diabetic, sedentary animals showed that even conventional
insulin treatment is capable of attenuating the reduced body and muscle weight reported in
previous models of STZ-induced T1DM. As DCT animals, which received both conventional
insulin treatment and sedentary lifestyles, did not show significant reductions in these measures,
it is apparent that even moderate hyperglycemia is insufficient to induce severe reductions in
body weight and muscle mass with mild insulin treatment. Moreover, DCT animals did not
exhibit reduced fiber CSA compared to CS animals (except for MHCIIx/IIb fibers), further
highlighting the utility of insulin treatment in maintaining fiber CSA.The only significant
difference in body weight observed was between DIT and DRE animals, where DRE body
weight was significantly lower (P<0.05) than DIT animals; however, as DIT and DRE muscle
weights did not differ this discrepancy could be due to differences in lean versus fat mass
accumulation. DIT animals displayed unexpected increases in muscle fiber CSA compared to
both CS and exercised animals, where MHCIIa and MHCIIa/IIx CSA’s were significantly larger
than all other groups.
In accordance with previous research, exercise did not result in gross hypertrophy of
plantaris muscles, although exercise modality did have significant and varied effects on the
hypertrophy of specific muscle fiber populations 61. In general, DHE animals exhibited
maintenance of fiber CSA, where DRE and DCE animals displayed specific fiber populations
with markedly increased CSA’s. Although aerobic endurance training has been shown to be
sufficient to induce hypertrophy in oxidative fibers (MHCI, MHCIIa), the lack of fiber CSA
increase relative to sedentary control and diabetic animals in DHE animals seems to indicate that
the effects of aerobic exercise were limited to protection from atrophy, possibly through
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increased PGC-1α expression 23,106. As expected, both DRE and DCE groups displayed
significant but unique differences in glycolytic fiber CSA’s. While DRE and DCE animals
exhibited increases in MHCIIa, MHCIIa/IIx, MHCII, and MHCIIx/IIb, only DCE MHCIIb CSA
was significantly greater than all other treatment groups. It is possible that the consecutive nature
of training in DRE animals, where resistance training was performed 5 days per week, resulted in
insufficient recovery time and thus inhibited the hypertrophy of MHCIIb fibers. Comparatively,
DCE animals engaged in alternating aerobic endurance and resistance training, allowing greater
time for muscle recovery while still carrying similar weight loads during resistance training. As
these findings seem to indicate that combined exercise training may be superior in terms of
maintaining muscle mass and increasing muscle fiber size across the spectrum of oxidative and
glycolytic fibers, further studies investigating combined training in humans with T1DM are
necessary. In general, further support for the notion of a preferential utilization of combined
training in T1DM patients may be gleaned from the fact that high intensity anaerobic training
performed prior to aerobic endurance training has been shown to reduce the risk of post-exercise
hypoglycemia, which is the primary concern of many T1DM patients engaging in exercise
45,46,107

. In summary, the present study provided important insights into the nature of diabetic

myopathy’s fiber specific CSA effects in different insulin therapy regimens and exercise training
modalities; however, identifying the molecular mechanisms responsible for these differential
effects should be the subject of future studies in order to better characterize these adaptations or
identify potential pharmaceutical targets.
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A1. Streptozotocin Induction
REVISION DATE: 13/06/2012
PURPOSE:
To induce Type I diabetes in rats
MATERIALS:
Gloves
Lab Coat
Streptozotocin (STZ)
5X Stock Citric Acid/Citrate Buffer
- Anhydrous Citric Acid
- Sodium Citrate Dihydrate
- MilliQ Deionized Water
13M HCl
3 Falcon Tubes
Sterile Filter
EQUIPMENT:
Biological Safety Cabinet
Weigh Scale
pH Meter
PROCEDURE:
Preparing 5X Citric Acid/Citrate Buffer
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add:
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate
ii. 23.8g Sodium Citrate Dihydrate (Sigma), Mix into…
iii. 175mL of MilliQ water
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH)
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml mark (pH
will move slightly). If satisfied with the pH, adjust volume in a 250 ml graduated cylinder and
filter in a 0.2µm filter.
3. Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection
**NOTE Animals should be pre-weighed prior to making up STZ to ensure accurate amounts of
STZ to be prepared.
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of distilled
water filtered through a 0.2µm syringe filter. Check the pH. This gives you a working
concentration of 153 mM
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2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of concentrated
HCl to the buffer, checking pH in between until desired pH is reached.
3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe filter as
before). If pH is below 4.5, restart.
4. Weigh out an appropriate amount of STZ for the number of animals (see calculations below)
that will be injected in a 15 minute time frame.
Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g (avg. weight of
rats to be injected), you will require a minimum of 40mg.
20mg/kg X 0.2kg = 4mg per animal
The amount of STZ weighed out should be more than the minimum as some solution will be lost
in filtering. (4mg (per animal) X 12 rats = 48mg total (0.048g)
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume). Shake to
dissolve powder (approx. 1min). Sterile filter using a 0.2µm syringe filter. Ex. 48mg STZ ÷ 3
mL buffer = 16mg/mL solution 4mg ÷ 16mg/mL solution = 0.25mL
6. STZ is time dependent and must be used within 15 minutes
Injecting and Follow-Up of the Animals
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of 20mg/mL (in
this example, 0.25mL). Do not use anymore STZ solution more than 15 minutes after it has been
dissolved in the sodium citrate buffer.
2. Dispose of any container having come into contact with the STZ (in either powder or
dissolved form) into a biohazardous waste receptacle. Dispose of needles into a sharps container.
3. Return injected rats to their cage. Record the date of STZ injection and add a biohazard label
to the cage (leave biohazard label on cage for at least 3 days following the last injection).
4. Repeat this procedure the following day.
5. Check blood glucose daily. Diabetes is achieved with two non-fasting blood glucose readings
of >18 mmol Diabetes should be achieved after 5-8 injections (i.p. 20mg/kg).
Reference: Low dose STZ induction protocol. Animal Models of Diabetic Complications
Consortium AMDCC Protocols.200
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A2. Insulin Pellet Implant
REVISION DATE: 13/06/2012
MATERIALS:
LinShin LinPlant Insulin Pellet
Rat anesthetic – Isoflurane
Ampicillin
Sterile water
1ml syringe with 25 g needle
10% providone-iodine solution
gauze (or swab)
Tissue forceps
Scalpel handle and blades (or scissors)
Silk suture
Needle drivers
EQUIPMENT:
Isofluorane Anaesthetic Machine
Hair clippers
Heat lamp
Special Safety:
Must don lab coat and gloves before handling rodents. Any bite or scratch that breaks the skin
must be thoroughly scrubbed with soap and water (report to Occupational Health and Safety).
PROCEDURE:
Pellet implantation (for a rat):
1. Anesthetize the animal using the isofluorane machine by placing it in the induction chamber.
Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the stopcock valve so gas reaches
the chamber. Keep in chamber until the animal is unconscious.
2. Remove the animal and place its nose in the nose cone, reduce the isofluorane to 3% to
maintain the plane of anesthesia.
3. Shave the area where the pellet is to be implanted.
4. Using gauze (or a swab), apply 10% providone-iodine solution to the skin, followed by 70%
ethanol, to disinfect the site of insertion.
5. Hold the skin with forceps and make a subcutaneous incision.
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the puncture
site to a depth of at least 2 cm.
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7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse with saline
and insert into the subcutaneous region.
8. Use 1 pellet for the first 350g of body weight.
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providone-iodine
solution over the opening.
10. Close the incision by suturing.
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
12. Record on the cage card that insulin pellets have been implanted.
Pellet removal:
1. Anesthetize the animal as described above for implantation.
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by applying
10% providone-iodine solution followed by 70% ethanol.
3. Using a scalpel (or scissors), make an incision through the skin superficial to the location of
the pellets. 4. Using forceps, remove the pellet. Some connective tissue may need to be cut away
using scissors. Discard the pellet.
5. Close the incision by suturing.
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.
7. Record on the cage card that the pellets have been removed.
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A3. Immunohistochemistry Protocol for Myosin Heavy Chain Isoforms
Advance Preparation
1. Serial 10µm-thick plantaris cryosections, adhered to VWR Superfrost® Plus microslides,
stored at -30°C
2. Ensure all slides are labelled with group, animal number, and slide identification with
fine tipped pencil
3. Prepare blocking solution aliquots in 1.5 mL Eppendorf tubes and store at -30°C until
use:
BS-1: 10% (v/v) horse serum + 1% (w/v) BSA (ALB001.50, Bioshop) in Tween-PBS
(pH 7.4)
BS-2: 10% (v/v) goat serum + 1% (w/v) BSA (ALB001.50, Bioshop) in Tween-PBS (pH
7.4)
4. Ensure adequate supply of the following items and solutions:
- Corning coverslips (#1, 22 x 55 mm)
- Krystalon™ Harleco (EM Science) mounting medium
- 10x PBS Stock: KCl 2.0g
NaCL 80g
Na2HPO4: 11.5g
KH2PO4: 2.0g
Bring to 1L with ddH2O
Adjust pH to 7.4
- 1 x PBS (re-adjusted to pH 7.4
- 1 x Tween-PBS: 1 x PBS + 0.5 mL Tween-20 (Fisher Scientific) per 1L, re-adjust pH
to 7.4
- 30% H2O2 (Caledon Laboratory Chemicals), stored at -30°C
- 100% ethanol
- Xylenes
- The following Vector Lab products: ImmunEdge hydrophobic barrier pen
Avidin-Biotin Blocking Kit (SP-2001)
DAB Substrate Kit (SK-4100)
- ABC Peroxidase Staining Kit (#3202, Thermo Scientific)
- Primary anti-bodies (see below)
- Vector biotinylated secondary anti-bodies: horse anti-mouse IgG (H+L) (BA-2000)
goat anti-mouse IgG (H+L) BA-9200)
5. Dehydration tanks, 150 mL each of: 2 x 70% EtOH, 2 x 95% EtOH, 2 x 100% EtOH, 2 x
100% xylene
- Seal tanks with paraffin wax to prevent evaporation
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6. Determine and record specific slide stain designations

Immunohistochemistry Protocol
Day 1
1. Remove slides from freezer.
2. Cover bottom of humidity chambers with dH20 soaked paper towels – place slides on
racks so that edges hang overhang slightly. Allow slides to reach RT in humidity
chambers for ~10 min.
3. Double circle sections with ImmEdge hydrophobic barrier pen.
4. Wash 1 x 5 min in Tween-PBS, 2 x 5 mins PBS.
5. Incubate in 3% H202 for 1 x 15 min at RT.
6. Wash 1 x 10 min in Tween-PBS, 1 x 5 min min in PBS.
7. Prepare the blocking solution/Avidin mixture by adding 4 drops of Avidin D to each ml
of blocking solution (BS-1 or BS-2). Approx. 60 µl are required for each section.
Incubate for 1 hr at RT. Thaw primary antibodies on ice.
8. Knock off excess blocking solution.
9. Apply approx. 60 µL of dilute primary antibody which has been diluted in the appropriate
blocking solution/Biotin mixture (4d Biotin per ml of blocking solution) per section.
Cover control sections with blocking solution/Biotin mixture without primary antibody.
Cover humidity chamber and incubate at 4°C overnight.
Primary
Antibody
BA-D5

Blocking
Solution
BS-1

Dilution

SC-71

BS-2

1:10

6H1

BS-2

1:10

BF-F3

BS-1

1:100

1:20

Day 2
1. Wash 1 x 5 mins Tween-PBS, 1 x 5 mins PBS.

Secondary
Antibody
biotinylated
horse-anti-mouse
IgG (H+L)
biotinylated
horse-anti-mouse
IgG (H+L)
biotinylated
goat-anti-mouse
IgG (H+L)
biotinylated
goat-anti-mouse
IgG (H+L)

Dilution
1:200

1:200

1:200

1:400
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2. Prepare appropriate biotinylated 2° antibody at 1:400 or 1:200 in the corresponding
species blocking solution (BS-1 or BS-2).
3. Apply 60 µL of biotinylated 2° Ab per section, and incubate 60 for 1 hour at RT.
4. Prepare ABC Peroxidase Staining Kit: ex. 2 drops of reagent A + 2 drops of reagent B to
10 mL of PBS. Allow to stand for 30 min at RT before use.
5. Wash 1 x 5 mins Tween-PBs, 1 x 5 mins PBS.
6. Apply 60 µL of ABC Peroxidase Stain solution and incubate for 45 min at RT.
7. Wash 1 x 5 mins Tween-PBS, 1 x 5 mins PBS.
8. Prepare DAB substrate: to each 2.5 ml of dH20 add
- 1 drop of buffer stock
- 2 drops of DAB stock and mix well
- 1 drop of H202 stock and mix well
- 1 drop of Nickel stock and mix well
** 1 drop = ~ 50 µL**
9. Apply ample substrate solution (DAB/NiCl2) to each section and incubate for 6-8 min at
RT.
10. Rinse in dH20 to stop the reaction, place slides in in carriage.
11. Dehydrate rapidly: 3 mins in 70% ethanol, 1 min in 95% ethanol x 2, 1 min in 100%.
ethanol; clear in 100% xylene for 1 min.
12. Adhere coverslips with mounting medium.
13. Dispose of excess DAB/NiCl2 solution in designated DAB waste bottle.
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A4. Metachromatic Dye Myosin ATPase Histochemical Stain
Advance Preparation:
1. Acidic pre-incubation solution: 0.49% KCH3COO (w/v)
0.26% CaCl2·2H2O (w/v)
- adjust pH to 4.4 with glacial acetic acid immediately
prior to use
2. 0.1 Tris buffer: 12.10g Trizma base
2.60g CaCl2·2H2O
-makes 1L, bring pH to 7.8
3. 1% Calcium Chloride Dihydrate Solution: 10g CaCl2·2H2O
-add to 1L ddH2O
4. 0.1% toluidine blue solution: 0.1% toluidine blue (w/v) for desired volume
- ex. 50 mL of solution = 50 mg toluidine blue, mix well
5. 150 mL each of 95% ethanol, 2 x 100% ethanol, 1 x 100% xylene
6. ATP Incubation solution: 0.4% glycine (w/v)
0.42% CaCl2·2H2O (w/v)
0.32% NaCl (w/v)
0.19% NaOH (w/v)
0.3% ATP (w/v)
-adjust pH to 9.4 with 5N HCl immediately prior to use
- prepare this solution immediately prior to staining
Staining Protocol:
1)
2)
3)
4)
5)
6)
7)
8)

Incubate 8 mins at RT in pre-incubation solution
Wash 3 x 2 mins in Tris buffer
Incubate 30 mins at RT in incubation solution
4 dips x 3 changes in CaCl2 2H2O solution
Incubate 90s in 0.1% toluidine blue solution
Rinse in running ddH2O for 30s (max.)
Dip 5 x in 95% ethanol, 5 times in 2 changes of 100% ethanol, incubate 1 min in xylene
Mount with toluene based mounting medium
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